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For an adoptive T cell immunotherapy to successfully treat cancer, T cells must 
be able to recognize tumor antigen, expand and persist in the tumor microenvironment, 
and deliver its effector function. Treatment of B cell acute lymphoblastic leukemia (B-
ALL) using human T cells modified to express a “second generation” CD19-targeted 
chimeric antigen receptor (CAR), which includes the CD28 co-stimulatory signaling 
domain (19-28z) along with the CD3 zeta chain signaling domain, has been successfully 
demonstrated in both the pre-clinical and clinical settings. However, application of CAR 
therapy for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and solid 
tumors remains a challenge. Here, we present preclinical studies demonstrating that 
further modifying 19-28z CAR T cells to additionally secrete a recombinant fusion 
protein of the pro-inflammatory interleukin 12 (IL-12) (19-28z/mIL-12 CAR T cells) 
enhances the potency of adoptive T cell immunotherapy. We demonstrate that these 19-
28z/mIL-12 “armored” CAR T cells display increased proliferation, up-regulation of 
 perforin and granzyme B, as well as a central memory-like phenotype when compared 
to T cells transduced to express the 19-28z CAR alone. In vivo, treatment of systemic 
NALM-6 B-ALL tumor-bearing SCID-Beige mice with 19-28z/mIL-12 CAR T cells 
significantly improved survival when compared to mice treated with T cells modified 
to express the 19-28z CAR alone. Furthermore, in contrast to T cells modified to express 
the 19-28z CAR alone, 19-28z/mIL-12 CAR T cells resist CD4+CD25hiFOXP3+ Treg-
mediated immunosuppression in vitro and successfully eradicate Raji Burkitt’s 
lymphoma tumor in SCID-Beige tumor-bearing mice previously infused with CD19-
targeted CAR modified Tregs. These findings have important implications for future 
clinical trials with CAR T cells designed to enhance the clinical outcomes of relapsed 
B-CLL as well as solid tumor malignancies. 
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CHAPTER 1: INTRODUCTION 
 
Cancer Immunotherapy 
As early as the 1700s, evidence of spontaneous remission of malignant disease 
in cancer patients with concomitant bacterial infection has been documented (Starnes, 
1992). However, it was not until the 1890s when William Coley, a New York surgeon, 
first took advantage of this phenomenon in benefiting cancer patients.  Coley observed 
that sarcoma patients who suffered from erysipelas, an acute Streptococcus bacterial 
infection, had spontaneous tumor regression (Coley, 1896). Attributing the tumor 
regression to toxins induced by the Streptococcus bacteria, Coley initially treated 
sarcoma patients with live Streptococcus infection. However, the risk of uncontrollable 
Streptococcus infection led to the use of a mixture composed of heat-killed Gram-
positive Streptococcus pyrogenes combined with Gram-negative Serratia marcescens. 
Coley’s toxin, as such mixture of Gram-positive and negative bacteria has come to be 
known, has since been applied in many types of cancer with inconsistent results. While 
the exact mechanism of action in Coley’s toxin was not known at the time, the early 
success of this therapy has opened the field of cancer immunotherapy (Starnes, 1992). 
The principle that T cells can eradicate tumor can be traced to evidence of graft-
versus-leukemia (GVL) in patients undergoing allogeneic bone marrow transplantation 
(allo-BMT) for hematological malignancies. Patients undergoing allo-BMT have lower 
risk of relapse when compared to receiving syngeneic BMT. Graft-versus-host disease 
(GVHD) following BMT is also associated with reduced risk of relapse. The lower risk 
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of relapse as seen in allo-BMT and GVHD can be attributed to GVL of T cells attacking 
host tumor as T cell depletion resulted in increased risk of relapse (Porter and Antin, 
1999). Moreover, adoptive T cell therapy utilizing donor-derived T cells, a procedure 
known as donor lymphocyte infusion (DLI), induces tumor remission in relapsed 
patients of chronic myelogenous leukemia (CML) following allo-BMT (Cullis et al., 
1992). 
The presence of lymphocyte infiltration in spontaneous cancer regression 
provides further evidence of T cell-mediated immunity against tumor (Rosenberg et al., 
1972). Human tumor infiltrating lymphocytes (TILs) derived from resected melanoma 
contain T cells that specifically recognize autologous tumor (Muul et al., 1987). This 
knowledge led to the first demonstration that adoptively transferring autologous TILs 
can mediate tumor regression in metastatic melanoma (Rosenberg et al., 1988). 
Adoptive cell transfer (ACT) therapy with TIL infusion has thus far achieved success 
in melanoma and cervical cancer (Rosenberg and Restifo, 2015). In addition to TILs, 
host T cells can be genetically modified to express anti-tumor T cell receptors (TCRs) 
and chimeric antigen receptors (CARs) for ACT. ACT therapy with TCR-modified T 
cells targeting the NY-ESO-1 antigen expressed in synovial sarcoma was the first 
reported targeting of nonmelanoma solid tumor (Robbins et al., 2011). Recently, ACT 
therapy with CAR-modified T cells also showed promising results in the treatment of 
hematological malignancies (van der Stegen et al., 2015). 
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Chimeric Antigen Receptor T Cells 
The history of chimeric antigen receptors (CARs) can be traced back to the early 
1990s after the ζ-chain of the CD3 complex was first cloned (Weissman et al., 1988). 
Pivotal studies on leukemic T cells demonstrated the feasibility of inducing activation 
of T cells expressing chimeric receptors composed of CD3 ζ-chain fused to the 
extracellular domains of CD8, CD4, or CD25 (Irving and Weiss, 1991; Letourneur and 
Klausner, 1991; Romeo and Seed, 1991). Eshhar and colleagues further generated the 
first CAR by fusing a single-chain variable fragment (scFv) to the CD3 ζ-chain (Eshhar 
et al., 1993). This scFv, derived from the variable fragments of the immunoglobulin 
heavy and light chains, can induce T cell activation upon recognition of the hapten 
trinitrophenyl. The success in Eshhar’s seminal study on scFv-CD3ζ CAR meant that it 
was possible to induce T cell activation in response to virtually any surface-exposed 
antigen to which a cognate scFv can be generated. This is an attractive tool that can be 
applied to cancer immunological research as T cells can be engineered to express a CAR 
that target any surface-exposed tumor associated antigen (TAA). 
T Cell Activation and CAR Design: In the classical definition of T cell 
activation, a T cell requires two signals to be fully activated. The first signal (signal 1) 
is provided by antigen-specific recognition of TCR (Smith-Garvin et al., 2009). TCR 
signaling can further be amplified and modulated by co-stimulation (signal 2) provided 
by antigen presenting cells (APCs). A classic example of co-stimulation is CD80 and 
CD86 expressed on the surface of APCs that stimulate CD28 expressed on the surface 
of T cells. Co-stimulatory receptors include both constitutively expressed moieties such 
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as CD28 and CD27 as well as activation-induced moieties such as 4-1BB, GITR, OX-
40, and ICOS (Sanmamed et al., 2015). TCR engagement in the absence of co-
stimulation may lead to a T cell unresponsive state known as anergy. Co-stimulation 
protects T cells from anergy and activation-induced cell death (AICD). Once a T cell 
becomes fully activated, the T cells rapidly proliferate and upregulate cytotoxic 
molecules. A proportion of the activated T cells eventually differentiate into memory T 
cells. These long-lived T cells can be loosely divided into two major types: effector 
memory (TEM) and central memory (TCM) T cells. TEM cells are more differentiated as 
characterized by reduction of CCR7 and CD62L expression. TCM cells are less 
differentiated and retain high expression of CCR7 and CD62L (Kaech and Cui, 2012). 
CAR Development 
A chimeric antigen receptor (CAR) is a fusion receptor that combines antigen 
recognition property of an immunoglobulin with T cell activation. A T cell engineered 
to express CAR, therefore, acquires the ability to become activated upon recognizing 
cell surface antigens in a manner analogous to an antibody. This unique property of 
CAR T cells has recently emerged to become a promising area of research in the field 
of cancer immunotherapy. 
First Generation CAR 
Eshhar’s TNP-targeted CAR is now considered to be a first generation CAR 
(Figure 1.1). A first generation CAR provides only one signal (signal 1) to a CAR-
expressing T cell via CD3ζ induction of downstream phosphatidyl inositol and tyrosine 
kinase pathways along with calcium influx, which then leads to cytotoxic activity 
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against the target cell (Sadelain et al., 2013). Gong and colleagues first demonstrated 
the efficacy of first generation CAR in the context of tumor cells by generating a 
chimeric antigen receptor specific to prostate-specific membrane antigen (PSMA) 
known as Pz1 (Gong et al., 1999). Pz1 CAR T cells were demonstrated to readily lyse 
prostate cancer cells in vitro. However, Pz1 CAR T cells did not readily secrete IL-2 
and were unable to expand upon repeated antigen exposure. 19z1 CAR T cells, which 
targets the common B cell antigen CD19 expressed on B cell tumors, show similar anti-
tumor cytotoxic activity in vitro, but have limited anti-tumor response in vivo (Brentjens 
et al., 2003). It became apparent that co-stimulation is necessary to successfully induce 
a sustained CAR T cell anti-tumor response in vivo. Brentjens and colleagues 
demonstrated that 19z1 CAR T cells can eradicate tumor cells that express the co-
stimulatory molecule CD80 such as Raji Burkitt’s lymphoma tumor cells in vivo, but 
have limited anti-tumor efficacy against CD80 deficient acute lymphoblastic leukemia 
(ALL) NALM-6 tumor cell line. 
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Second Generation CAR 
While preliminary data suggested the need for CAR T cells to receive co-
stimulation, many tumors fail to express co-stimulatory ligands. The limited success of 
first generation CAR T cells in vivo led to the generation of CAR T cells that incorporate 
the signaling domain of co-stimulatory molecules, now collectively known as second 
 
Figure 1.1 Development of chimeric antigen receptors 
First generation CARs contain the cytoplasmic signaling domain of the CD3 
TCRζ chain. Second generation CARs contain the cytoplasmic signaling 
domain of the TCRζ chain and one additional cytoplasmic signalling domain of 
co-stimulatory receptors such as CD28, 4-1BB, and OX-40. Third generation 
CARs contain two signalling domains of costimulatory receptors in addition to 
the signalling domain of CD3 TCRζ chain. “Armored” CAR introduces 
additional genes such as cytokines or co-stimulatory ligands to a CAR to 
enhance the function of CAR T cells. TM, transmembrane domain. 
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generation CAR T cells (Figure 1.1). This provides signal 2 in addition to signal 1, 
preventing T cell anergy. Brentjens and colleagues at Memorial Sloan Kettering Cancer 
Center (MSKCC) tested whether incorporating the co-stimulatory molecules CD28, 
DAP10, 4-1BB, and OX-40 in the CAR design enhances the anti-tumor efficacy of CAR 
T cells (Brentjens et al., 2007). Among these, 19-28z CAR T cells, which incorporates 
the signaling domain of CD28 in the CAR, was demonstrated to have the most robust 
phenotype as characterized by enhanced proliferation and increased secretion of IL-2, a 
marker of T cell co-stimulation, as well as IFN-γ in vitro in comparison to the other co-
stimulatory CAR receptors tested. More importantly, 19-28z CAR T cell therapy 
enhances the survival of NALM-6 tumor-bearing SCID-Beige mice as compared to 
mice treated with 19z1 CAR T cells (Brentjens et al., 2007). Rosenberg and colleagues 
at the National Cancer Institute (NCI) further confirmed these findings by comparing a 
similar CD19-targeted CAR that incorporate the CD28 and 4-1BB signaling domains. 
The CD19-targeted CAR T cells lysed primary human chronic lymphocytic leukemia 
cells (CLL) in which the CD28 signaling domain-containing CAR T cells produce more 
IFN-γ and IL-2 as compared to the  4-1BB CAR in vitro (Kochenderfer et al., 2010). 
June and colleagues at the University of Pennsylvania (UPenn) confirmed the superior 
anti-tumor response of second generation CAR T cells compared to first generation 
CAR T cells, but 4-1BB CAR T cells were shown to survive longer in the context of a 
xenotransplant tumor mouse model as compared to CD28 CAR T cells (Milone et al., 
2009). Investigators at the Fred Hutchinson Cancer Center (Fred Hutch), Baylor College 
of Medicine (Baylor), and MD Anderson have also generated versions of second 
generation CAR incorporating either a CD28 or 4-1BB signaling moiety in their designs, 
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demonstrating anti-tumor efficacy in the context of B cell tumors (Kowolik et al., 2006; 
Terakura et al., 2012; Vera et al., 2006). 
The design of the second generation CAR T cells at these institutions differ in 
many respects. The key differences among the six different institutions are summarized 
in Table 1.1. Besides differences in the use of CD28 or 4-1BB as co-stimulatory 
molecules, the spacer regions between the scFv and co-stimulatory signaling domain as 
well as the method of genetic modification also differ among the groups. The majority 
of institutions utilizes a viral vector, either retrovirus or lentivirus, for genetic 
modification. On the other hand, Cooper and colleagues have developed the Sleeping 
Beauty System that integrates DNA into the genome by means of electroporation of 
DNA plasmids carrying transposon and transposase (Singh et al., 2008). The transposon 
carrying the CAR can efficiently integrate at random sites in the genome (Morgan and 
Kakarla, 2011). It remains to be determined whether CD28 or 4-1BB containing second 
generation CAR T cells has superior anti-tumor efficacy. Collectively, the early pre-
clinical studies have demonstrated superior anti-tumor efficacy of second generation 
CAR T cells as compared to first generation CAR T cells. These studies have led to 
early success in clinical trials for the treatment of some hematological tumors such as B 
cell acute lymphoblastic leukemia (B-ALL). 
Due to lack of in vivo efficacy of first generation CAR T cells for the treatment 
of B cell tumors in pre-clinical studies, most of the early clinical trials have been largely 
focused on second generation CAR T cells with the exception of Brenner and colleagues, 
who treated patients in a clinical trial with a combinational therapy of CD19-targeted 
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CAR T cells that encodes the CD3ζ domain alone or both CD28 and CD3ζ domains 
(Savoldo et al., 2011). The injected CAR T cells were monitored and the results 
demonstrated enhanced persistence of the CAR T cells expressing the CD28 signaling 
domain as compared to the CAR T cells lacking a CD28 signaling domain.
 
Third Generation CAR 
In addition to first and second generation CAR T cells, many have investigated 
combining two co-stimulatory domains within the cytoplasmic tail in CAR design 
(Zhong et al., 2010). However, these so-called third generation CAR T cells do not 
necessarily improve the efficacy of CAR therapy as compared to therapy with second 
generation CAR T cells (Morgan et al., 2010). For example, Tamma and colleagues 
Table 1.1 CD19-targeted chimeric antigen receptor design 
 
Institute scFv clone Spacer regions Signaling 
Domains 
Genetic 
modification 
methods 
Baylor FMC63 Human IgG1 
CH2CH3 domain 
CD28 
costimulation 
CD3ζ activation 
Retroviral 
transduction 
NCI FMC63 No hinge CD28 
costimulation 
CD3ζ activation 
Retroviral 
transduction 
MD 
Anderson 
FMC63 Modified 
human IgG4 
CD28 
costimulation 
CD3ζ activation 
Sleeping beauty 
transposon 
Electroporation 
MSKCC SJ25C1 No hinge CD28 
costimulation 
CD3ζ activation 
Retroviral 
transduction 
UPenn FMC63 Human CD8α 
hinge 
4-1BB 
costimulation 
CD3ζ activation 
Lentiviral 
transduction 
Fred 
Hutch 
FMC63 Modified 
human IgG 
4-1BB 
costimulation 
CD3ζ activation 
Lentiviral 
transduction 
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engineered CD19-targeted CAR containing an intracellular domain of CD3ζ chain along 
with both 4-1BB and CD28 domains (1928BBζ). Treatment of 1928BBζ  CAR T cell 
therapy resulted in delayed tumor progression and enhanced survival of NOD/SCID 
CD19-tumor bearing mice compared to second generation CAR treatment (Tammana 
et al., 2010). This improved therapeutic benefit was also seen in a PSMA-targeted third 
generation CAR T cells expressing both CD28ζ and 4-1BB domains (Zhong et al., 2010). 
On the other hand, no therapeutic benefit was observed in third generation CD28ζ and 
4-1BB domain-expressing CAR T cells engineered by Milone and colleagues (Milone 
et al., 2009). 
Advantages of CAR T cells 
CAR T cells have a number of distinct advantages compared to T cells 
engineered to express tumor-specific TCRs. It is well known that cancer cells 
downregulate human leukocyte antigen (HLA) as a mechanism of immune escape 
(Hicklin et al., 1999). While a TCR can only recognize protein antigen in the context of 
HLA, a CAR can recognize any surface antigen independent of HLA expression. In 
addition to proteins, a CAR can also recognize carbohydrates and glycolipids, 
expanding potential targets (Sadelain et al., 2013). Until now, CAR T cells were known 
to target only native cell surface antigens, limiting the repertoire of TAAs. However, a 
preliminary study demonstrating the feasibility of CAR T cells to target the human 
intracellular protein, Wilms’ tumor gene 1 (WT1) in the context of HLA-A0201 has 
been reported at a recent American Society of Hematology (ASH) annual meeting 
(Rafiq et al., 2014). 
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Clinical Studies with CD19-Targeted CAR T Cells 
B-cell hematological malignancies have been extensively studied in clinical 
trials using second generation CAR T cells. CD19, a relatively ideal tumor associated 
antigen (TAA), has been the main target used to treat most B cell malignancies. CD19 
is expressed in most B-cell leukemias and lymphomas and its expression in normal 
tissues is limited to the B cell lineage. While targeting CD19 results in B cell aplasia, 
such “on-target off-tumor” toxicity can be managed with infusions of intravenous 
immunoglobulin (IVIG) (Anderson et al., 2007). 
B-ALL: Among the B cell malignancies investigated in clinical trials, treating 
B cell acute lymphoblastic leukemia (B-ALL) with second generation CD19 CAR 
therapy has demonstrated the most promising clinical results. B-ALL is an acute form 
of leukemia that is characterized by the accumulation of malignant pre-B cell 
lymphoblasts. Until the advent of CAR therapy, patients with B-ALL had few treatment 
options, largely a combination of chemotherapy to induce remission followed by 
consolidation and maintenance of residual disease (Bassan and Hoelzer, 2011). 
While complete remission (CR) has reached about 85-90% over the last decade 
using conventional methods for the treatment of B-ALL among pediatric patients, it 
remains a challenge to treat the adult form of B-ALL. Until the advent of CAR therapy, 
salvage therapy for relapsed B-ALL has a historical remission rate of about 30% 
(Gökbuget et al., 2012). Brentjens and colleagues at MSKCC were the first to report the 
results of CD19 CAR T cell therapy trial for the treatment of relapsed B-ALL. Among 
the 16 patients treated with CD19 CAR T cell therapy, there was an 88% overall rate of 
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patients with CR in which 44% of the patients received “standard-of-care” allogeneic 
hematopoietic stem cell transplantation (HSCT) (Brentjens et al., 2013; Davila et al., 
2014). Grupp and colleagues at UPenn reported 90% CR among the 30 patients treated 
in their clinical trial (Maude et al., 2014). Rosenberg and colleagues at NCI reported an 
overall CR rate of 70% among the 21 pediatric and young adult patients that were treated 
with CD19 CAR therapy. Ten of the 12 patients with minimal residual disease (MRD)-
negative status received HSCT (Lee et al., 2015). Early clinical results from MD 
Anderson and Fred Hutchinson Center have also been reported at a recent ASH annual 
meeting with some encouraging results (Kebriaei et al., 2014; Turtle et al., 2014). 
B-CLL: B-CLL is the most common form of hematologic malignancy in the 
Western world, and it is characterized by the accumulation of long-lived B lymphocytes 
in the bone marrow, lymphoid organs, and peripheral blood. B-CLLs are inefficient 
antigen presenting cells (APCs) with low expression of T cell co-stimulatory receptors 
CD80 and CD86, but expression of these co-stimulatory ligands can be induced by 
CD40L and soluble factors secreted by activated T cells (Romano et al., 2003). 
In contrast to the clinical trial results for the treatment of B-ALL using second 
generation CD19 CAR treatment, results in low grade B cell malignancies such as B-
CLL have been far more modest (Brentjens et al., 2011; Kochenderfer et al., 2013). June 
and colleagues at UPenn initially reported minimal residual disease MRD- CR in 2 of 3 
B-CLL patients treated with CD19 CAR therapy (Kalos et al., 2011; Porter et al., 2011). 
However, a more recent report on the result of 14 patients with relapsed and refractory 
B-CLL showed an overall response rate of 57% (8/14) of which four of the patients had 
13 
 
CR and four others had partial remission (PR) (Porter et al., 2015). In the study 
conducted at MSKCC, seven B-CLL patients were treated with CAR T cell therapy, 
four of which received preconditioning chemotherapy prior to treatment. None of the 
patients who received chemotherapy had a response, while three of the four patients 
who received chemotherapy experienced stable disease following CAR T cell infusion 
(Brentjens et al., 2011). Clinical studies reported at NCI described four patients who 
were treated with CAR T cell infusion after preconditioning with cyclophosphamide 
and fludarabine. Three of the four patients achieved classically defined CRs 
(Kochenderfer et al., 2015, 2012). 
DLBCL: In addition to B-ALL and B-CLL, clinical results have also been 
reported by multiple centers testing the efficacy of CD19 CAR therapy for the treatment 
of diffuse large B cell lymphoma (DLBCL). While 50-80% of patients with DLBCL are 
cured with standard induction therapy, relapse is the major cause of treatment failure 
that ultimately results in mortality of patients. MSKCC has reported preliminary results 
of 100% CR among the two follicular lymphoma (FL), three relapsed DLBCL, and one 
marginal zone lymphoma (MZL) patients treated with CAR T cell therapy (Sauter et al., 
2014). Kochenderfer and colleagues at NCI reported 1 CR and 4 PR among the eight 
DLBCL patients treated with CAR T cell therapy (Kochenderfer et al., 2014). 
Preliminary finding from a clinical trial at UPenn resulted in 2 CR among the 6 DLBCL 
patients treated with CAR therapy (Schuster et al., 2014). At MD Anderson, among the 
five DLBCL or FL patients treated, four patients achieved CR and one patient achieved 
PR (Kebriaei et al., 2014). 
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While these early clinical trials show great promise in the treatment of B-ALL 
with CD19 CAR therapy, several challenges of this therapy remains to be explored. 
First, all of the clinical trials thus far require the administration of a lymphodepletion 
regimen such as cyclophosphamide and fludarabine treatment prior to CAR T cell 
infusion. This can pose a challenge for elderly immunocompromised patients who may 
not be able to tolerate such a toxic treatment. CAR T cell therapy also induces 
neurological abnormalities characterized by seizures, aphasia, and encephalopathy. 
Furthermore, one of the major side effects of CAR therapy is the induction of large 
quantity of inflammatory cytokines that, on the one hand, promotes CAR T cell function 
and, on the other hand, also induces fever, hypotension, and hypoxia. These symptoms 
associated with increase in serum inflammatory cytokines are collectively termed 
cytokine release syndrome (CRS). C-reactive protein (CRP) have recently been 
identified as an indicator measuring the severity of CRS, and IL-6R blockade 
(tocilizumab) have been demonstrated to protect patients from the toxicities associated 
with CRS (Grupp et al., 2013). 
Etiologies of CAR T cell Treatment Failure 
Despite the successful clinical studies in treating patients with B-ALL, treating 
B-CLL and solid tumors remains a challenge. This can possibly be attributed to the 
immunosuppressive tumor microenvironment of B-CLL and solid tumors. 
Accumulation of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), 
tumor associated macrophages (TAMs) as well as the secretion of immunosuppressive 
cytokines and angiogenic factors all play a critical role in promoting tumor progression 
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and suppressing the function of CD4 and CD8 effector T cells (Teff) in the tumor 
microenvironment. 
Regulatory T cells (Tregs): Tregs, a specific subset of T cells that function to 
maintain immune tolerance, can be broadly classified into two groups. Natural Tregs 
(nTregs) are CD4+CD25+CD127loFOXP3+ T cells derived from the thymus that 
comprise approximately 5-10% of the CD4 T cell population in human and mice. Naïve 
CD4 T cells can also be induced with TGF-β and IL-2 to acquire suppressive function. 
CD4+CD25+FOXP3+ T cells derived from Teff cells in the periphery are known as 
induced Tregs (iTregs). Tregs were initially thought to function in a contact-dependent 
manner when Sakaguchi and colleagues demonstrated that adding neutralizing 
antibodies against TGF-β and IL-10 have no effect on Treg suppression in vitro 
(Takahashi et al., 1998). In contrast, more recent studies on the role of Tregs in 
controlling airway allergic responses demonstrated the possible role of IL-10 and TGF-
β in the suppressive function of Tregs in vivo (Hawrylowicz and O’Garra, 2005). 
Joetham and colleagues demonstrated that injection of IL-10 deficient Tregs had no 
effect on reducing airway hyperresponsiveness (AHR) of allergen challenged mice, 
whereas pre-incubation of Tregs with IL-10 before Treg transfer resulted in AHR 
suppression associated with elevated levels of bronchoalveolar lavage TGF-β levels 
(Joetham et al., 2007). Moreover, Vignali and colleagues reported that Tregs can 
suppress in a contact independent mechanism mediated by IL-35 secretion (Chaturvedi 
et al., 2011; Collison et al., 2007). By virtue of expressing the high affinity IL-2 receptor 
CD25, Tregs have also been proposed to function as a “cytokine sink” that deprives 
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actively dividing Teff cells of IL-2 essential for their survival (Thornton and Shevach, 
1998). 
The association of poor prognosis and Treg accumulation in human cancer has 
been well-documented. Zou and colleagues identified preferential accumulation of 
Tregs in advanced staged ovarian cancer patients (Curiel et al., 2004). FOXP3+ Tregs 
accumulate in high number among invasive breast cancer patients and has been 
identified as a risk factor of breast cancer relapse (Bates et al., 2006). In a correlation 
study of lung cancer patients, Patz and colleagues demonstrated that high infiltrating 
Treg/TIL ratio is associated with high risk of lung cancer relapse (Petersen et al., 2006). 
Others have also identified the negative risk factor of high Treg frequency in the context 
of hepatocellular carcinoma (Gao et al., 2007), renal cell carcinoma (Griffiths et al., 
2007), gastric cancer (Perrone et al., 2008), cervical cancer (Jordanova et al., 2008), and 
colorectal carcinoma (Sinicrope et al., 2009). Other than solid tumors, extensive studies 
have confirmed the increased levels of Tregs in the context of B-CLL, especially among 
patients at advanced stage of the disease (Jadidi-Niaragh et al., 2013). 
Myeloid-Derived Suppressor Cells (MDSCs): MDSCs are CD11b+GR1+ 
immature cells that exhibit strong immunosuppressive function in the context of cancer 
(Gabrilovich et al., 2012). The immunosuppressive effect of MDSCs has been examined 
in many types of cancer, including melanoma (Mandruzzato et al., 2009), colon cancer 
(Mandruzzato et al., 2009), prostate cancer (Vuk-Pavlović et al., 2010), and 
hepatocellular carcinoma (Hoechst et al., 2008). MDSC can broadly be divided into two 
types: monocytic MDSC and polymorphonuclear MDSC. Monocytic MDSCs express 
17 
 
monocyte markers F4/80, CD115, and CCR2, and suppress CD8 T cells predominantly 
by depriving CD8 T cells of L-ariginine through ARG1 expression and increasing the 
production of reactive nitrogen species (RNS) (Gabrilovich et al., 2012). 
Polymorphonuclear MDSCs are morphologically similar to neutrophils, but are less 
phagocytic. High levels of ARG1 expression and increased reactive oxygen species 
(ROS) enable polymorphonuclear MDSCs to suppress activated T cells (Gabrilovich et 
al., 2012). 
Tumor Associated Macrophages (TAMs): In addition to MDSCs, 
macrophages that accumulate in the tumor microenvironment can acquire an 
immunosuppressive phenotype. These tumor-associated macrophages (TAMs) exhibit 
an M2 phenotype characterized by the high levels of IL-10 and low levels of IL-12 
expression. In contrast, “classically activated” M1 macrophages are characterized by 
high levels of IL-12 and low levels of IL-10 expression and are tumoricidal (Gabrilovich 
et al., 2012). TAMs can suppress immunity by several mechanisms. Secretion of CCL22 
by TAMs recruits Tregs to the tumor, and secretion of TGF-β and prostaglandin E2 
(PGE2) further contribute to immune suppression (Curiel et al., 2004; Gabrilovich et al., 
2012). TAMs can also directly induce apoptosis of PD-1+ T cells via PD-L1 expression 
(Kuang et al., 2009). 
Programmed death ligand 1 (PD-L1): PD-L1, also known as B7-H1, belongs 
to the B7 family of ligands that include co-stimulatory molecules such as CD80 and 
ICOS-L (Collins et al., 2005). PD-L1 is overexpressed in both murine and human 
tumors (Keir et al., 2008). Programmed death 1 (PD-1), the receptor of PD-L1, is 
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expressed on the surface of activated T cells. PD-L1 ligation inhibits CD3/CD28-
induced Akt activity which in turn leads to reduction in the expression of BCL-XL, an 
antiapoptotic cell survival factor (Parry et al., 2005). This also results in decreased 
proliferation and IL-2 production (Carter et al., 2002). Overcoming PD-L1-mediated 
immune suppression is therefore another critical aspect of the tumor microenvironment. 
Interleukin 12 and CAR T Cell Therapy 
IL-12 Structure: Interleukin 12 (IL-12) is a heterodimeric protein composed of 
two subunits with molecular mass of 35 (IL-12-p35) and 40 (IL-12-p40) kDs. 
Covalently linked IL-12-p35 and p40 subunits combine to form IL-12-p70, a cytokine 
that has pleiotropic effect in many cell types of the immune system (Lasek et al., 2014). 
IL-12-p40 can also form homodimers of IL-12-p40/p40 that suppress the biological 
effect of IL-12-p70 via receptor competition (Ling et al., 1995; Mattner et al., 1993). 
For the purpose of this thesis, IL-12 will refer to the heterodimer IL-12-p70 form. 
IL-12 receptor: The receptor of IL-12 is composed of two amino acid chains, 
IL-12Rβ1 and IL-12Rβ2. IL-12Rβ1 is constitutively expressed in peripheral blood 
mononuclear cells (PBMCs) and widely expressed in most cell lines in the 
hematopoietic lineage but absent in the nonhematopoeitic lineage (Wu et al., 1996). IL-
12Rβ2 is not expressed in naïve T cells, but induced upon T cell receptor activation. IL-
12, IFN-γ, TNF-α, and CD28 stimulation can further augment IL-12Rβ2 expression in 
activated T cells (Afkarian et al., 2002; Rogge et al., 1997; Szabo et al., 1997). IL-12Rβ2 
expression has also been observed in natural killer (NK) cells, natural killer T (NKT) 
cells, myeloid cells and tonsillar B cells (Airoldi et al., 2000; Grohmann et al., 1998; 
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Presky et al., 1996). IL-12Rβ1 is primarily responsible for IL-12 binding, while IL-
12Rβ2 is required for IL-12 signaling (Presky et al., 1996). IL-12 induces Janus kinase 
2 (Jak2) and tyrosine kinase 2 (Tyk2) phosphorylation, which in turn leads to signal 
transducer and activator of transcription (STAT)-4 phosphorylation in T and NK cells 
(Bacon et al., 1995; Thierfelder et al., 1996). 
IL-12 function: IL-12 was originally discovered in 1989 and it was known as 
Natural Killer cell stimulatory factor (NKSF) due to its biological effect on NK cells 
(Kobayashi et al., 1989). IL-12 is primarily produced by antigen presenting cells (APCs) 
such as macrophages, dendritic cells, and B cells upon Toll-like receptor (TLR) 
engagement (Tugues et al., 2015). IFN-γ, IL-15, and CD40L stimulation on APCs can 
further amplify the production of biologically active IL-12 (Kuwajima et al., 2006; Ma 
et al., 1996; Schulz et al., 2000). On the other hand, TGF-β1 and IL-10 can negatively 
regulate IL-12 production (D’Andrea et al., 1993; Du and Sriram, 1998). IL-12 has been 
shown to enhance the proliferation of NK cells and T cells (Perussia et al., 1992). 
Furthermore, IL-12 has the potential to enhance cytotoxicity in NK cells and T cells by 
upregulating granzyme B and perforin (Aste-Amezaga et al., 1994; Sakedo et al., 1993). 
IL-12 also functions to promote Th1 immune response by inducing IFN-γ production 
while inhibiting the differentiation of Th2, Treg, and Th17 cells (Djuretic et al., 2007; 
Manetti et al., 1993; Prochazkova et al., 2012). Enhanced IFN-γ secretion further leads 
to enhanced IgG2a B cell class-switching, while IL-12 inhibits IgE production (Morris 
et al., 1994). 
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IL-12-mediated tumor suppression: The therapeutic benefit of IL-12 as an 
agent to induce anti-tumor response has been recognized as early as 1993 when Brunda 
and colleagues reported intraperitoneal (i.p.) administration of IL-12 induced antitumor 
response against B16 melanoma, M5975 sarcoma, and RENCA renal cell carcinoma 
(Brunda et al., 1993). This anti-tumor response was in part dependent on CD8 T cells 
as depletion of CD8 T cells resulted in decreased anti-tumor efficacy in the study. The 
contribution of NK and NKT cells in IL-12-mediated anti-tumor response has also been 
investigated in EL4-S3 lymphoma, B16F10 melanoma, and RM-1 prostate carcinoma 
(Smyth et al., 2000). Interestingly, it was demonstrated that NKT cells played a critical 
role in anti-tumor efficacy at low dose and delayed IL-12 treatment, while NK cells 
were the primary catalyst under high dose IL-12 treatment conditions. Since Brunda’s 
early studies, preclinical studies on systemic intravenous (i.v.), intraperitoneal (i.p.), 
subcutaneous (s.c.), and intratumoral (i.t.) delivery of recombinant IL-12 have all 
indicated promising therapeutic potential of IL-12 against various immune mouse 
models of cancer (Colombo and Trinchieri, 2002). 
Despite the promising results in preclinical studies of IL-12-mediated 
suppression, high toxicity of systemic recombinant IL-12 administration presents a 
major impediment for clinical application (Leonard et al., 1997). Furthermore, early 
clinical studies in metastatic renal carcinoma, melanoma, colon carcinoma, recurrent 
ovarian cancer, and neck and head carcinoma showed very few PRs and CRs among i.v. 
IL-12-treated patients (Atkins et al., 1997; Hurteau et al., 2001; Leonard et al., 1997). 
In contrast to systemic administration of IL-12, localized i.t. delivery of a plasmid 
encoding IL-12 showed some clinical benefits in melanoma (Heinzerling et al., 2005; 
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Mahvi et al., 2007). Moreover, encouraging clinical results have been demonstrated in 
s.c. administration of IL-12 in hematological malignancies. For instance, an overall 
response rate of 56% was seen in cutaneous T cell lymphoma patients receiving s.c. IL-
12 treatment (Rook et al., 1999). S.c. IL-12 treatment of non-Hodgkin’s B cell 
lymphoma (NHL) patients resulted in 21% PR or CR and about 50% stable disease (SD) 
(Younes et al., 2004). Treating NHL with s.c. IL-12 in combination with anti-CD20 
rituximab further improved clinical outcomes, resulting in 25% CR and 42% PR (Ansell 
et al., 2002). 
The therapeutic potential of IL-12 in tumor suppression and the promising 
results of second generation CAR T cells in cancer immunotherapy prompted the studies 
in this dissertation. Combining IL-12 and CAR T cells in the form of an IL-12-secreting 
CAR T cells may improve CAR T cell therapy and possibly overcome the suppressive 
tumor microenvironment. In this dissertation, we describe the effect of IL-12 on the 
biology of CAR T cells and demonstrate its therapeutic potential in enhancing anti-
tumor efficacy of CAR T cell therapy.  
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CHAPTER 2: MATERIALS AND METHODS 
 
Cell Culture 
Tumor Cells: Raji (American Type Culture Collection (ATCC), Manassas, VA) 
and NALM-6 (courtesy of David M. Nanus, Weill Cornell Medical College, New York, 
NY) tumor cell lines were maintained in RPMI 1640 (The Core Media Preparation 
Facility, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Atlanta Biologicals, 
Norcross, GA), nonessential amino acids, HEPES buffer (Gibco, Invitrogen, Waltham, 
MA), sodium pyruvate (Gibco), β-mercaptoethanol (Gibco), L-glutamine (2 mmol/L; 
Gibco), penicillin (100 U/mL; Gibco), and streptomycin (100 µg/mL; Gibco). 
Artificial Antigen Presenting Cells (AAPC): NIH-3T3 mouse fibroblast 
AAPCs – 3T3(PSMA+/CD80+) (Gong et al., 1999),  3T3(CD19+/CD80+) (Brentjens et 
al., 2003), and 3T3(MUC-16ecto+/CD80+) (Koneru et al., 2015) – have been previously 
published. The AAPCs were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM; The Core Media Preparation Facility, MSKCC, New York, NY) 
supplemented with 10% heat-inactivated donor calf serum (Thermo Fisher Scientific, 
Waltham, MA), L-glutamine (2 mmol/L; Gibco, Invitrogen, Waltham, MA), penicillin 
(100 U/mL; Gibco), and streptomycin (100 µg/mL; Gibco). 
Retroviral Producer Cell Lines: 293 Gibbon ape leukemia virusaLV-9 19-28z, 
19-28z/mIL-12, 19-28z/hIL-12, Pz1, Pz1/mIL-12, 4H11-28z, 4H11-28z/mIL-12, and 
4H-1128z/hIL-12 were maintained in DMEM supplemented with 10% heat-inactivated 
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(FBS; Atlanta Biologicals, Norcross, GA), L-glutamine (2 mmol/L; Gibco, Invitrogen, 
Waltham, MA), penicillin (100 U/mL; Gibco), and streptomycin (100 µg/mL; Gibco). 
T Cells: Human T cells were cultured in human T cell media – RPMI 1640 
supplemented with 10% heat-inactivated FBS (The Core Media Preparation Facility, 
MSKCC), recombinant human IL-2 (100 IU/mL; Proleukin, Novartis, Basel, 
Switzerland), L-glutamine (2 mmol/L; Gibco), penicillin (100 U/mL; Gibco), and 
streptomycin (100 µg/mL; Gibco). 
Generation of Retroviral Constructs 
Generation of 19-28z (CD19-specific) (Brentjens et al., 2007), Pz1 (PSMA-
specific) (Gong et al., 1999), and 4H11-28z (MUC16-specific) (Chekmasova et al., 
2010) scFv-CD28-CD3ζ chain fusion proteins have been previously described. For 
CD19-specific CAR, we cloned the heavy (VH)- and light (VL)-chain variable regions 
from hybridoma cell line SJ25C1–derived cDNA by PCR and fused these coding 
regions with a (Gly3Ser)4-coding DNA fragment. The human CD8 leader peptide was 
ligated to the 5’ end of the resulting scFv. The hinge and transmembrane coding regions 
of the human CD28 gene and the cytoplasmic domains of the human CD28 and CD3 ζ-
chain were ligated to the 3’ end of the scFv. 
The 19-28z, Pz1, and 4H11-28z retroviral constructs were further modified to 
include a gene encoding the murine flexi-IL-12 (courtesy of Alan Houghton and Jedd 
Wolchok (Ferrone et al., 2006)) or human flexi-IL-12 (Wagner et al., 2004) with a 
serine-glycine repeat linker between the p35 and p40 domains with a CD8 leader peptide 
distal to the CAR gene and preceded by an internal ribosome entry site (IRES). The 
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resulting fusion genes were cloned into the modified moloney murine retroviral vector 
SFG (Rivière et al., 1995). Please refer to Figure 4.1 for a schematic diagram of 19-28z 
and 19-28z/mIL-12 constructs with the corresponding components of the CAR depicted 
in transduced CAR T cells. 
293 H29 Transfection/293 GaLV-9 Transduction 
VSV-G pseudotyped retroviral supernatants derived from transduced gpg29 
fibroblasts were used to construct stable 293 GaLV-9 envelope-pseudotyped retroviral 
producing cell lines as described previously using polybrene (Gong et al., 1999). 293 
H29 packaging cell line was plated at 30-50% confluence and CaPO4 transfected with 
DNA encoding CAR construct using the ProFection Mammalian Transfection System 
(Promega, Madison, WI). The supernatant from the transiently transfected 293 H29 cell 
lines was collected every 24 hours for three days. Each day the viral supernatant along 
with polybrene (800 µg/mL; AmericanBio, Inc., Natick, MA) was added to a 30-50% 
confluent 293 GaLV-9 retroviral producing cell line for stable transduction.  The 
transduced 293 GaLV-9 retroviral producing cell line was assessed for CAR expression 
by flow cytometry following staining with CAR-specific monoclonal goat anti-mouse 
phycoerythrin (PE)-conjugated antibody (Invitrogen, Waltham, MA) for CD19-targeted 
CAR, AlexaFluor647-conjugated Armenian hamster antibody that specifically binds to 
the 4H11-28z CAR (Memorial Sloan-Kettering Cancer Center Monoclonal Antibody 
Facility), and anti-PSMA fluorescein isothiocyanate (FITC)-conjugated antibody 
(Abcam, Cambridge, United Kingdom). 
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T Cell Isolation 
Human peripheral blood mononuclear cells (PBMCs) were isolated from 
peripheral blood of healthy donors under Institutional Review Board approved protocol 
95-091 using BD Vacutainer CPT tubes (Becton Dickinson, East Rutherford, NJ) or 
from a leukopak (New York Blood Center, New York, NY) and fractionated using 
density gradient centrifugation with Accu-Prep™ Lymphocytes (Axis-Shield, Dundee, 
Scotland). For isolation using BD Vacutainer CPT Tubes (Becton Dickinson), blood 
collected in CPT tubes was centrifuged at 1700 RCF (relative centrifugal force) for 20 
min with no brake. The buffy coat was collected and washed twice with phosphate-
buffered saline (PBS) at 1300 rpm centrifugation. The isolated PBMC was resuspended 
in human T cell media at 3 x 106 cells/mL concentration. For isolation using leukopak 
and Accu-Prep™ Lymphocytes (Axis-Shield), 35 mL of blood was transferred to 50 mL 
tubes and each tube was underlaid with 10 mL of lymphoprep. The tubes were 
centrifuged at 800 RCF for 20 min with no brake. The buffy coat was collected, washed 
as described above, and the isolated PBMC was resuspended in human T cell media at 
3 x 106 cells/mL concentration. 
CD4+CD25hiFoxp3+ nTreg Isolation and Expansion 
CD4+CD25hiFoxp3+ natural Tregs (nTregs) were isolated from PBMCs using 
Human CD4+CD25HIGH T Cell Isolation Kit (Stemcell Technologies, Vancouver, 
Canada) according to manufacturers’ instructions. Using antibodies bound to magnetic 
beads, PBMCs were negatively selected with monoclonal antibodies targeting non-CD4 
T cell antigens (CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD123, TCRγ/δ, 
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CD66b and glycophorin A), and then positively selected with CD25 antibody. Purity of 
nTregs was assessed with flow cytometry following staining with anti-human CD4, 
CD25, and FOXP3 antibodies. 
The isolated nTregs were stimulated with Dynabeads® Human T-Activator 
CD3/CD28 for T cell Expansion and Activation (Gibco) at 1:1 bead:cell ratio and 
maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS, IL-2 (500 
IU/mL every two to three days; Proleukin, Novartis), and rapamycin (100 ng/mL; Sigma 
Aldrich, St. Louis, MO) (Lee et al., 2011). Expanded nTregs were reassessed for FOXP3 
expression after three weeks of expansion by flow cytometry following staining with 
anti-human CD4, CD25, and FOXP3 antibodies. 
Retroviral Gene Transfer of T Cells and nTregs 
T Cells: Gene transfer of retroviral vector into effector T cells has been 
previously described (Brentjens et al., 2007; Lee et al., 2009). T cells were activated 
with phytohemagglutinin (2 µg/ml; Sigma Aldrich) and IL-2 (100 IU/ml; Proleukin, 
Novartis) for 48 hours and transduced in 6-well non–tissue culture plates (Becton 
Dickinson) coated with 15 µg/ml retronectin (Takara Biomedicals, Otsu, Japan). For 
three consecutive days, fresh retroviral producer supernatant was added to T cells daily 
followed by centrifugation at 3,200 rpm for one hour at 30°C. The transduction 
efficiency of CAR T cell was assessed by flow cytometry following staining with CAR-
specific monoclonal goat anti-mouse PE-conjugated antibody (Invitrogen, Waltham, 
MA). For in vivo tumor models, CAR T cells were expanded by re-stimulating with 
3T3(CD19+/CD80+), 3T3(PSMA+/CD80+), or 3T3(MUC-16ecto+/CD80+) AAPC to 
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generate sufficient quantity of tumor-specific T cells (Kim et al., 2004; Latouche and 
Sadelain, 2000). 
nTregs: Isolated nTregs were activated with Dynabeads® Human T-Activator 
CD3/CD28 for T cell Expansion and Activation (Gibco, Invitrogen) at 1:1 bead:cell ratio 
and cultured in RPMI 1640 supplemented with 10% heat-inactivated FBS, IL-2 (500 IU; 
Proleukin) and rapamycin (100 ng/mL) for 48 hours, (Battaglia et al., 2005; Strauss et 
al., 2007) and transduced using the same protocol of T cell transduction. The 
transduction efficiency in nTregs was assessed by flow cytometry following staining 
with CAR-specific monoclonal goat anti-mouse PE-conjugated antibody (Invitrogen). 
T Cell Proliferation 
Carboxyfluorescein succinimidyl ester (CFSE) Proliferation Assay: 1 x 106 
CAR T cells were labeled with 5 µmol/L CFSE (Invitrogen) and stimulated with anti-
CD3/CD28 beads (Invitrogen) at 1:3 bead:cell ratio in the presence or absence of 
recombinant murine IL-12 (mIL-12; 10 ng/mL) for 72 hours in 24-well tissue culture-
coated plates (Becton Dickinson, East Rutherford, NJ) in the absence of exogenous IL-
2 followed by flow cytometry analysis. Percentage of T cell proliferation was assessed 
by gating on the population with diluted CFSE expression compared to unstimulated T 
cells. 
For nTreg suppression experiments, 5 x 105 CFSE-labeled CAR T cells were co-
cultured with titrated numbers of purified autologous CAR+CD4+CD25+Foxp3+ natural 
Tregs (nTregs) (Oberg et al., 2006). T cell co-cultures were stimulated with anti-
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CD3/CD28 beads (Invitrogen) at 1:3 bead:cell ratio and proliferation was assessed by 
flow cytometry at 72 hours. 
CD4 and CD8 Proliferation: CD4 and CD8 T cells were isolated from T cells 
previously transduced with CAR using Dynabeads Untouched Human CD4 T cells and 
Dynabeads Untouched Human CD8 T cells (Invitrogen) magnetic bead isolation kits, 
respectively. For CD4 T cell isolation, T cells were negatively selected with antibodies 
targeting CD8, CD14, CD16, CD19, CD36, CD56, CDw123, and glycophorin A. For 
CD8 T cell isolation, T cells were negatively selected with antibodies targeting CD4, 
CD14, CD16, CD19, CD36, CD56, CDw123, and glycophorin A. 1 x 106 CD4 T and 
CD8 T cells were stimulated with anti-CD3/CD28 beads (Gibco) at 1:3 bead:cell ratio. 
Exogenous mIL-12 (10 ng/mL; R&D System, Inc., Minneapolis, MN) was added to the 
media daily for the duration of the experiment. Total cell number of viable cells was 
enumerated by GuavaViaCount (Millipore, Billerica, MA) on days 0, 3, 7, 10, 14, and 
21 after stimulation. Fold expansion of cells were calculated by dividing the cell counts 
at the specified time points by the initial number of viable cells. 
NALM-6 and Raji Tumor-Stimulated Proliferation: 1 x 106 CAR+ T cells 
were labeled with CellVue Claret Far Red Fluorescent dye (Sigma Aldrich) and co-
cultured with 1 x 106 NALM-6 or Raji tumor cells in 12-well tissue culture-coated plates 
(Becton Dickinson). Total cell counts of viable cells were enumerated by 
GuavaViaCount (Millipore) and flow cytometry analysis of CD3, CD19, and CAR 
expression was assessed on days 0, 3, 7, 10, 14, and 21 after co-culture. Total CAR+ T 
cell counts were calculated at the specified time points and the relative fold expansion 
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was calculated by dividing the cell counts at the specified time points by the initial 
number of CAR+ T cells. 
Proliferation with Repeated Antigen Exposure: 9 x 106 CAR+ T cells were 
cultured in three wells of 70% confluent 3T3(CD19+/CD80+) AAPCs in 6-well tissue 
culture-coated plates. Every seven days, CAR expression was assessed by flow 
cytometry and total cell counts were enumerated by using a hemocytometer and 
nonviable cells were excluded by trypan blue. 9 x 106 CAR+ T cells recovered from the 
previous week were re-stimulated with 3T3(CD19+/CD80+) AAPCs. Total CAR+ T cell 
counts were calculated at the specified time points and the relative fold expansion was 
calculated by dividing the cell counts at the specified time points by the initial number 
of CAR+ T cells. 
T Cell Cytotoxicity Assays 
Chromium Release Assay: Cytolytic capacity of CAR T cells was assessed 
using a standard chromium release assay as described previously (Gong et al., 1999). 
Transduced CAR T cells were incubated for 4 hours at different effector to target (E:T) 
ratios with 51Cr-labeled target cells at 37°C. The amount of 51Cr in the supernatant was 
determined with a Top Count automated gamma counter (Perkin Elmer, Waltham, MA). 
Percentage of specific 51Cr release was calculated by (51Cr release – spontaneous 
release)/(maximum 51Cr release – spontaneous release) x 100. 
Cytotoxic Activity at 72 hours: 1 x 106 CAR+ T cells were labeled with CellVue 
Claret Far Red Fluorescent dye (Sigma Aldrich) and co-cultured with 1 x 106 NALM-
6 tumor cells in 12-well tissue culture-coated plates. Total cell count was assessed using 
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a hemocytometer with trypan blue exclusion of nonviable cells and CD19 and CD3 
expression were assessed by flow cytometry at 72 hours after co-culture. Total number 
of NALM-6 tumor cells is calculated based on the percentage of CD19+ cells and 
absolute cell counts. 
nTreg Suppression Assays: To assess nTreg-mediated inhibition of CAR T cell 
cytotoxicity, 1 x 106 CAR T cells were co-cultured with 1 x 106 nTregs in RPMI media 
for 24 hours in 12-well tissue culture treated plates. 1 x 106 Raji tumor cells were 
subsequently added to the culture. Tumor lysis was subsequently assessed by flow 
cytometry to detect residual CD19+ tumor cells. 
Cytokine Detection Assay 
Cytokine levels in tissue culture supernatant were quantified using multiplex 
Human Cytokine Detection System (Millipore) in conjunction with the Luminex IS 100 
system and IS 2.2 software (Luminex Corporation, Austin, TX) according to the 
manufacturer’s instructions. 
Mouse Tumor Models 
NALM-6 B-ALL tumor model: 8- to 12-week-old Fox Chase SCID-Beige 
(CB17.Cg-PrkdcscidLystbg-J/Crl) mice (Charles Rivers, Wilmington, MA) were injected 
with 1 x 106 NALM-6 tumor cells intravenously (i.v.) followed by a single injection 
(i.v.) of 1 x 107 CAR T cells on day 6. Mice were monitored clinically for disease 
progression and were euthanized when disease was evident as characterized by ruffled 
fur, weight loss, and/or hind limb paralysis. In a separate study to assess CAR T cell 
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survival, mice were injected (i.v.) with 1 x 106 NALM-6 tumor cells followed by a single 
injection (i.v.) of 1 x 107 CAR T cells on day 14. Retro-orbital blood samples were then 
collected 7 days and 14 days following CAR T cell infusion to assess persistence of 
CAR T by flow cytometry analysis of CD3 and CAR expression. 
nTreg suppression tumor model: 5 x 105 Raji tumor cells were infused (i.v.) 
on day 1, 1 x 107 CAR+ nTregs were infused (i.v.) on day 5, and 1 x 107 CAR T cells 
were infused (i.v.) on day 6 (Lee et al., 2011). All in vivo studies were performed in 
accordance with the Institutional Animal Care and Use Committee at Memorial Sloan-
Kettering Cancer Center (approved protocol #00-05-065). 
Bioluminescent Imaging of NALM-6 Tumors in vivo: Bioluminescence 
imaging was done using Xenogen IVIS Imaging System (Perkin Elmer) with Living 
Image 4.4 software (Perkin Elmer) for acquisition of imaging data sets. Mice were 
injected intraperitoneally (i.p.) with 150 mg/kg D-luciferin (Perkin Elmer) resuspended 
in 200 µL PBS. Five minutes later, mice were anesthetized with 2% isoflurane and 
imaged. Image acquisition of ventral surface was performed with a 25 cm field of view 
at medium binning level for 30 s exposure time or 1 s exposure time when the 
bioluminescent intensity reached saturation. 
Flow Cytometry 
Flow cytometry was performed using BD LSRII (Becton Dickinson) or Gallios 
Flow Cytometer (Beckman Coulter, Brea, CA) and analyzed with Flowjo10 software. 
Raji and NALM-6 tumor cells were stained with anti-human CD19 antibody 
(Invitrogen). For phenotypic characterization, human T cells were stained with anti-
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human CD8 (Invitrogen), CD4, CD45RA, CCR7, and CD62L (eBioscience, Santa Clara, 
CA) antibodies. For granzyme B and perforin analyses, T cells were permeabilized with 
BD Cytofix/Cytoperm Kit and stained with anti-human granzyme B and perforin 
antibodies (eBioscience). Analysis of T cell exhaustion was assessed by staining CAR 
T cells with anti-human PD-1 and TIM-3 antibodies (eBioscience). Analysis of nTregs 
was assessed by staining with anti-human CD4, CD25, CD127, and FOXP3 antibodies 
(eBioscience). CAR expression was assessed using CAR-specific monoclonal goat anti-
mouse phycoerythrin (PE)-conjugated antibody (Invitrogen) or PE-conjugated CAR-
specific 19E3 antibody (MSKCC monoclonal antibody core facility). All cells were stained 
with Fixable Viability Dye eFluor®450 (eBioscience). 
Statistical Analysis 
All analyses were calculated using GraphPad Prism 6 software. Log rank 
Mantel-Cox test was used to analyze survival studies, and Mann-Whitney test was used 
for other analyses.  
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CHAPTER 3: EFFECT OF EXOGENOUS IL-12 ON CAR T CELLS 
 
Exogenous IL-12 enhances 19-28z CAR T cell proliferation 
To evaluate the therapeutic benefit of IL-12 in the context of CD19-specific 
CAR T cells, we retrovirally transduced human peripheral blood mononuclear cells 
(PBMCs) with 19-28z CAR and cultured the cells in the presence or absence of 
exogenous recombinant murine IL-12 (mIL-12). Due to the cross-reactivity of mIL-12 
with human IL-12 receptor, we reasoned that mIL-12 would be appropriate for studying 
human T cells both in vitro and in xenotransplant mouse models (Schoenhaut et al., 
1992; Trinchieri, 1994). We stimulated 19-28z CAR T cells with anti-CD3/CD28 beads 
for 72 hours in the presence or absence of mIL-12 and monitored proliferation of the 
CAR T cells. Utilizing a CFSE proliferation assay, we observed a statistically significant 
increase in proliferation in 19-28z CAR T cells treated with mIL-12 as compared to the 
absence of mIL-12 stimulation  (p<0.05, n=7; Figure 3.1A). We further examined the 
effect of mIL-12 on the expansion of the CD4 and CD8 subsets of 19-28z CAR T cells 
over a three week period. We separated 19-28z CAR T cells into CD4 and CD8 
populations and stimulated the cells with anti-CD3/CD28 beads in the presence or 
absence of exogenous mIL-12. In both the CD4 and CD8 populations, the 19-28z CAR 
T cells that were treated with mIL-12 exhibited significantly increased expansion as 
compared to 19-28z CAR T cells cultured without mIL-12 (p<0.01, n=3; Figure 3.1B). 
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Exogenous IL-12 enhances cytotoxic activity of 19-28z CAR T cells 
We next studied the effect of IL-12 on the cytotoxic potential of 19-28z CAR T 
cells. We first examined the expression of two molecules critical for the cytotoxic 
activity of cytotoxic T lymphocytes (CTLs) – granzyme B (GzmB) and perforin (Pfn). 
Perforin secreted by CTLs binds to the plasma membrane of target cell and oligomerizes 
in a Ca2+-dependent manner to form large transmembrane pores that enable diffusion 
of granzymes into the target cell cytosol (Voskoboinik et al., 2015). Granzymes in turn 
induce apoptosis in the target cell by directly activating the pro-apoptotic factor Bid or 
indirectly through caspase 8 activation (Barry et al., 2000). Granzyme B is the most 
dominant pro-apoptotic granzyme which can induce apoptosis rapidly even in the 
 
 
Figure 3.1 Exogenous mIL-12 enhances 19-28z CAR T cell proliferation 
(A) CFSE proliferation assay showing percent proliferating CAR T cells after 
three days of anti-CD3/CD28 bead stimulation in the presence or absence of 
exogenous mIL-12. *p<0.05, n=7. (B) Expansion of 19-28z CD8 (circle) and 
CD4 (triangle) CAR T cells after anti-CD3/CD28 bead stimulation in the 
presence (unshaded) or absence (shaded) of exogenous mIL-12. Fold expansion 
of CAR T cells determined by enumeration with GuavaViaCount of viable cells 
and flow cytometry analysis of CAR expression. For comparison between mIL-
12 and non-IL-12 cultured groups, *p<0.05, **p<0.01, n=3. 
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context of low perforin levels (Voskoboinik et al., 2015). We observed that a higher 
percentage of 19-28z CAR T cells express granzyme B (p<0.05, n=4) and perforin 
(p<0.05, n=3) in the presence of exogenous mIL-12 as compared to 19-28z CAR T cells 
cultured in the absence of exogenous mIL-12 (Figure 3.2). 
 
Exogenous IL-12 induces a distinct pro-inflammatory Th1/Tc1-like phenotype in 
19-28z CAR T cells 
To determine the effect of mIL-12 on 19-28z CAR T cell function, we compared 
the cytokine secretion levels of 19-28z CAR T cells cultured in the presence and absence 
of exogenous mIL-12 after 48 hours of anti-CD3/CD28 bead stimulation. The mIL-12-
cultured 19-28z CAR T cells were characterized by a predominantly pro-inflammatory 
Th1/Tc1-type immune response. In both the CD4 and CD8 populations, a significantly 
 
 
Figure 3.2 Exogenous mIL-12 enhances granzyme B and perforin 
expression in 19-28z CAR T cells 
19-28z CAR T cells were cultured in the presence or absence of exogenous 
mIL-12 for seven days and assessed for the expression of (A) granzyme B 
(GzmB) and (B) perforin (Pfn) by flow cytometry. Data showing percentage of 
19-28z CAR T cells expressing GzmB and Pfn among the CD8 population. 
*p<0.05, n=4 (A), n=3 (B). 
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enhanced production of the Th1 cytokine IFN-γ (CD8: p=0.0149, n=3; CD4: p<0.0001) 
was secreted from 19-28z CAR T cells cultured in the presence of exogenous mIL-12 
as compared to 19-28z CAR T cells cultured in the absence exogenous mIL-12 (Figure 
3.3). At the same time, the production of the Th2 cytokines IL-5 (CD8: p=0.0001, n=3; 
CD4: p=0.0002, n=3) and IL-13 (CD8: p=0.0002, n=3; CD4: p<0.0001, n=3) was 
reduced in the mIL-12-cultured 19-28z CAR T cells as compared to 19-28z CAR T cells 
cultured in the absence of mIL-12 (Figure 3.3).  Among the CD4 population, the Th17 
cytokine IL-17A was also significantly reduced in the mIL-12-cultured 19-28z CAR T 
cells as compared to the 19-28z CAR T cells cultured in the absence of mIL-12  
(p<0.0001, n=3; Figure 3.3). 
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Figure 3.3 Exogenous IL-12 induces 19-28z CAR T cells towards a distinct 
pro-inflammatory Th1/Tc1-like phenotype 
19-28z CAR T cells were stimulated with anti-CD3/CD28 beads in the presence 
or absence of exogenous mIL-12 for 48 hours and the supernatant was assessed 
by luminex. Secretion of IFN-γ, IL-5, IL-13, and IL-17A in CAR T cells after 
stimulation. *p<0.05, n=3; NS, p=not significant. 
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CHAPTER 4: IL-12-SECRETING CAR T CELLS 
 
Generation of IL-12-secreting CAR T cells 
Having established the beneficial effect of exogenous mIL-12 on CAR T cell 
proliferation, cytotoxic potential, and cytokine production, we reasoned that CAR T 
cells further modified to constitutively express mIL-12 may have similar increased 
proliferation and enhanced in vitro and in vivo anti-tumor function. Furthermore, 
generating IL-12-secreting CAR T cells allows targeted delivery of IL-12 into the tumor 
microenvironment, reducing the cytotoxic effect associated with systemic recombinant 
IL-12 administration. We inserted an IRES element followed by a fusion gene encoding 
the p35 and p40 subunits of murine IL-12 (flexi-IL-12) (Ferrone et al., 2006) into the 
19-28z retroviral CAR construct (Figure 4.1). Similarly, we generated two other IL-12-
secreting control CAR constructs by inserting mIL-12 in the constructs encoding the 
prostate-specific membrane antigen (PSMA)-specific CAR (Pz1) and the ovarian cancer 
antigen MUC16ecto (4H11-28z) to generate Pz1/mIL-12 and 4H11-28z/mIL-12 CAR 
constructs, respectively. 
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19-28z/mIL-12 CAR T cells secrete functional murine IL-12 
The 19-28z/mIL-12 retroviral CAR construct was transduced into a stable 293-
GaLV9 retroviral producer cell line. The 19-28z/mIL-12 retroviral producer cell line 
expressed the CAR (Figure 4.2A) and secreted mIL-12 after 24 hours of culture (Figure 
4.2B). To confirm that the mIL-12 secreted by the 19-28z/mIL-12 producer cell line is 
biologically active, we cultured PBMCs with the supernatant from the 19-28z or 19-
28z/mIL-12 producer cell lines for 24 hours and assessed the level of IFN-γ secretion 
as it has been established that mIL-12 induces IFN-γ secretion (Chan et al., 1991). 
 
 
Figure 4.1 Chimeric antigen receptor retroviral construct 
Schematic diagram of (A) 19-28z and (B) 19-28z/mIL-12 retroviral constructs. 
scFv, single chain variable fragment; TM, transmembrane domain; IRES, 
internal ribosome entry site; mIL-12f, murine flexi-IL-12. 
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Compared to cells stimulated with 19-28z producer supernatant, PBMCs cultured with 
19-28z/mIL-12 producer supernatant secreted a significantly greater amount of IFN-γ 
(p<0.05, n=4) (Figure 4.2C). 
 
19-28z/mIL-12 CAR T cells are characterized by a unique pro-inflammatory 
Th1/Tc1-like phenotype 
We next transduced human T cells to express both the 19-28z CAR and mIL-12. 
Comparable levels of retroviral gene transfer was observed following transduction with 
either 19-28z or 19-28z/mIL-12 vector (Figure 4.3A). As expected, only T cell modified 
with the 19-28z/mIL-12 vector secreted mIL-12 (Figure 4.3B). 
 
 
 
Figure 4.2 GaLV-9 19-28z/mIL-12 retroviral producer cell line validation 
(A) CAR expression in GaLV-9 19-28z and 19-28z/mIL-12 viral producer cell 
lines as assessed by flow cytometry following staining with monoclonal 
antibody that specifically binds the CAR-specific monoclonal goat anti-mouse 
PE-conjugated antibody. (B) mIL-12 expression in GaLV-9 CAR viral producer 
cell line was assessed by luminex after 24 hours of cell culture (*p<0.05, n=4). 
(C) GaLV-9 19-28z/mIL-12 viral producer cell line secreted functional mIL-
12. PBMCs were stimulated with supernatant from GaLV-9 19-28z or 19-
28z/mIL-12 viral producer cell line for 24 hours, and the supernatant from the 
PBMC cultures were analyzed for secretion of IFN-γ  by luminex (*p<0.05, 
n=4). 
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To determine the type of immune response 19-28z/mIL-12 CAR T cells 
produced in the context of tumor cells, we compared the cytokine levels secreted from 
19-28z and 19-28/mIL-12 CAR T cells after 24 hours of culture with NALM-6 or Raji 
tumors. In the context of NALM-6, we demonstrated that 19-28z/mIL-12 CAR T cells 
display a Th1/Tc1-like phenotype as characterized by elevated levels of IFN-γ (p<0.05, 
n=4) and lower levels of IL-5 (p<0.01, n=5), IL-13 (p<0.01, n=5), and IL-17A (p<0.05, 
n=4) compared to 1928z CAR T cells (Figure 4.4A). Stimulation of 19-28z or 19-
28z/mIL-12 CAR T cells with Raji tumors resulted in similar levels of cytokine 
secretion (Figure 4.4B). 
 
 
Figure 4.3 19-28z/mIL-12 CAR T cells secrete mIL-12 
(A) Comparable 19-28z and 19-28z/mIL-12 CAR expression in T cells after 
gene transfer as assessed by flow cytometry. (B) High levels of mIL-12 detected 
in supernatant from 19-28z/mIL-12 CAR T cells but absent in 19-28z CAR T 
cells at 24 hours after anti-CD3/CD28 bead stimulation as determined by 
luminex (*p<0.01, n=5). 
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19-28z/mIL-12 CAR T cells have enhanced proliferation compared to 19-28z CAR 
T cells and display a TCM-like phenotype 
We next assessed the proliferative capacity of CAR T cells by re-stimulating 
once with NALM-6 tumor cells and quantifying the number of viable CAR T cells over 
a three week period. 19-28z/mIL-12 CAR T cells have an increased expansion 
compared to 19-28z CAR T cells (Figure 4.5A, left panel). This increased expansion 
can be attributed to increased proliferation that can be observed as early as ten days after 
stimulation (p=0.05, n=3) (Figure 4.5A, right panel). Stimulation of CAR T cells with 
Raji tumor cells yielded similar enhanced proliferation in the 19-28z/mIL-12 CAR T 
cells as compared to 19-28z CAR T cells (Figure 4.5B). Furthermore, we observed that 
 
 
Figure 4.4 19-28z/mIL-12 CAR T cells have a Th1/Tc1-like phenotype 
Secretion of IFN-γ, IL-5, IL-13, and IL-17 in CAR T cells after CAR T cells 
were stimulated with (A) NALM-6 or (B) Raji tumor cells at 1:1 ratio for 24 
hours as assessed by luminex. *p<0.05, n=5. 
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at ten days following gene transfer, a significantly higher percentage of 19-28z/mIL-12 
CAR T cells are characterized by a CCR7+CD62Lhi central memory (TCM)-like 
phenotype (p<0.01, n=7) as compared to the 19-28z CAR T cell population (Figure 4.6). 
 
 
 
Figure 4.5 19-28z/mIL-12 CAR T cells have enhanced proliferation as 
compared to 19-28z CAR T cells 
19-28z/mIL-12 CAR T cells have increased proliferation compared to 19-28z 
CAR T cells in the context of (A) NALM-6 and (B) Raji tumors. CAR T cells 
were labeled with CellVue Claret Far Red Fluorescent dye and co-cultured with 
Raji cells at a ratio of 1:1. Fold expansion (left panel) of CAR T cells determined 
by enumeration with GuavaViaCount of viable cells and flow cytometry 
analysis of CAR expression. Flow cytometry plot displays representative 
CellVue Claret Dye dilution on day 10 (right panels). For all time points, 
*p=0.05, n=3. 
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In vivo, CAR T cells may be prone to prolonged antigen exposure. To assess the 
long-term proliferative potential of 19-28z/mIL-12 CAR T cells under such conditions, 
we tracked the expansion of 19-28z and 19-28z/mIL-12 CAR T cells after repeated 
weekly stimulation with 3T3(CD19+/CD80+) artificial antigen presenting cells 
(AAPCs). The 19-28z CAR T cells stopped expanding after the 3rd stimulation, while 
19-28z/mIL-12 CAR T cells continued to expand after the 4th stimulation (Figure 4.7). 
 
 
Figure 4.6 19-28z/mIL-12 CAR T cells express both CCR7 and CD62L 
Higher percentage of CCR7+CD62Lhi T cells in 19-28z/mIL-12 CAR T cell 
population compared to 19-28z CAR T cell population observed at 10 days after 
initial gene transfer as assessed by flow cytometry. (A) Representative FACS 
plot of CCR7 and CD62L expression. (B) Percentage of CCR7+CD62L+ T cells. 
*p<0.01, n=7. 
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IL-12 has been associated with the induction of exhaustion in T cells in the 
context of follicular B cell non-Hodgkin’s lymphoma tumor (Yang et al., 2012). 
Exhaustive T cells are characterized by elevated PD-1 and TIM-3 expression (Crespo 
et al., 2013). To determine whether 19-28z/mIL-12 CAR T cells exhibits a more 
exhausted phenotype, we checked the expression of PD-1 and TIM-3 in CAR T cells 
that have been stimulated twice with 3T3(CD19+/CD80+) AAPCs. However, we did not 
observe any significant difference in the percentage of PD-1+TIM-3+ cells between 19-
28z and 19-28z/mIL-12 CAR T cell populations (Figure 4.8). 
 
 
 
Figure 4.7 19-28z/mIL-12 CAR T cells retain proliferative capacity after 
repeated antigen exposure 
3x106 19-28z or 19-28z/mIL-12 CAR T cells were stimulated with 
3T3(CD19+/CD80+) AAPC weekly as indicated by black arrows. Fold 
expansion of CAR T cells determined by enumeration with GuavaViaCount of 
viable cells and flow cytometry analysis of CAR expression. Data represent two 
independent experiments. 
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19-28z/mIL-12 CAR T cells have enhanced cytotoxic activity compared to 19-28z 
CAR T cells 
We next compared the expression of granzyme B and perforin in 19-28z and 19-
28z/mIL-12 CAR T cells. Production of granzyme B (p<0.0001, n=5) and perforin 
(p<0.0001, n=3) was observed in a higher percentage of 19-28z/mIL-12 CAR T cells 
when compared to that of 19-28z CAR T cells indicating a potentially greater cytotoxic 
capacity (Figure 4.9A-B). As expected, 19-28z CAR T cells can effectively lyse NALM-
6 tumors compared to control Pz1 CAR T cells (Figure 4.9C). We did not observe any 
advantage in the ability of 19-28z/mIL-12 CAR T cells to kill NALM-6 tumor cells in 
a 4 hour 51Cr-release assay (Figure 4.9C). However, there was a significant decrease in 
overall NALM-6 tumor cell number (p<0.01, n=7) following 72 hour co-culture with 
 
 
Figure 4.8 PD-1 and TIM-3 expression in CAR T cells 
19-28z and 19-28z CAR T cells were stimulated twice with 3T3(CD19+/CD80+) 
AAPC over two weeks. The percentage of PD-1+TIM-3+ cells was assessed by 
flow cytometry. NS, p=not significant, n=5. 
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19-28z/mIL-12 CAR T cells at a 1:1 effector:target (E:T) ratio when compared to co-
culture with 19-28z CAR T cells as assessed by flow cytometry (Figure 4.9D). 
 
  
 
 
Figure 4.9 19-28z/mIL-12 CAR T cells have enhanced cytotoxic capacity 
compared to 19-28z CAR T cells 
(A) 19-28z/mIL-12 CAR T cells express significantly more granzyme B 
compared to 19-28z CAR T cells as assessed by intracellular flow cytometry 
(*p<0.0001, n=5). (B) 19-28z/mIL-12 CAR T cells express significantly more 
perforin as compared to 19-28z CAR T cells as assessed by intracellular flow 
cytometry (*p<0.0001, n=3). (C) 19-28z and 19-28z/mIL-12 CAR T cells lyse 
NALM-6 tumor cells at similar levels in a four hour 51Cr release assay. Data 
represent three independent experiments. (D) 19-28z/mIL-12 CAR T cells have 
enhanced cytotoxic activity as compared to 19-28z CAR T cells following 72 
hours co-culture with NALM-6 tumor at 1:1 E:T ratio as assessed by 
enumeration with GuavaViaCount of viable cells and flow cytometry analysis 
of CD19 expression. (*p<0.01, n=7). 
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CHAPTER 5: EFFICACY OF IL-12-SECRETING CAR T CELLS IN VIVO 
 
19-28z/mIL-12 CAR T cells eradicate systemic NALM-6 pre-B cell ALL tumors in 
SCID-Beige mice  
We previously demonstrated that NALM-6 tumor bearing SCID beige mice 
have enhanced survival when treated with 19-28z CAR T cells as compared to treatment 
with first generation 19z1 CAR T cells. However, such therapeutic benefit accounted 
for only 44% of the treated mice and only after four weekly 19-28z CAR T cell infusions 
with the first infusion administered one day after tumor injection (Brentjens et al., 2007). 
Considering the effects of mIL-12 in enhancing T cell proliferation, cytotoxic activity, 
and promoting a TCM-like phenotype in CAR
 T cells, we investigated the ability of 19-
28z/mIL-12 CAR T cells to eradicate NALM-6 tumors in SCID/Beige mice. We infused 
19-28z/mIL-12 or 19-28z CAR T cells seven days after tumor inoculation and 
monitored the mice for tumor progression. As controls, we also monitored the 
progression of mice infused with Pz1 or Pz1/mIL-12 CAR T cells targeting to the 
irrelevant PSMA antigen. All of the mice treated with control Pz1 CAR T cells died by 
day 29 (Figure 5.1). Furthermore, none of the Pz1/mIL-12 CAR T cell-treated mice 
survived beyond day 28, suggesting that mIL-12 secretion by non-tumor-targeting CAR 
T cells does not have any appreciable anti-tumor effect against NALM-6 tumors in this 
model. While 19-28z CAR T cell-treated mice exhibited delayed tumor progression 
compared to Pz1 (p<0.0001) and Pz1/mIL-12 (p<0.0001) control groups, all but one 
(6.67%) mouse eventually died of disease (Figure 5.1). Compared to the 19-28z CAR T 
cell-treated mice, the mice treated with 19-28z/mIL-12 CAR T cells had significantly 
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enhanced survival (p<0.0001) in which 93.3% of the mice survived and remained 
tumor-free on day 60. 
 
19-28z/hIL-12 CAR T cell therapy has reduced anti-tumor efficacy compared to 
19-28z/mIL-12 CAR T cell therapy in vivo 
While 19-28z/mIL-12 CAR T cell therapy improved anti-tumor efficacy 
compared to 19-28z CAR T cell treatment, it remains unclear whether the effect of IL-
12 is entirely autocrine as murine IL-12 can have an effect on many cell types. In a 
 
 
Figure 5.1 19-28z/mIL-12 CAR T cells eradicate systemic NALM-6 pre-B 
cell ALL tumors in SCID-Beige mice 
19-28z/mIL-12 CAR T cell treatment enhances survival compared to 19-28z 
CAR T cell-treated mice. SCID-Beige mice were inoculated (i.v.) with 1x106 
NALM-6 tumor cells on day 0 and 1x107 CAR T cells on day 6. Data showing 
93.3% long-term survival of 19-28z/mIL-12 CAR T cell-treated mice compared 
to 6.67% survival in 19-28z CAR T cell-treated mice (p<0.0001, n=15 from two 
independent experiments). 19-28z CAR T cell-treated mice have significantly 
enhanced survival compared to Pz1 (p<0.0001) and Pz1/mIL-12 (p<0.0001) 
CAR T cell-treated mice. Pz1/mIL-12 CAR T cell-treated mice do not have 
enhanced survival compared to Pz1 CAR T cell-treated mice (p=0.6291). 
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SCID-Beige mouse, the B and T cell compartments are compromised due to the Prkdc 
mutation, and the beige mutation impairs NK cell cytotoxic activity (Croy and Chapeau, 
1990; Roder and Duwe, 1979). IL-12 has been demonstrated to enhance NK cell 
function and rescue NK cell activity in the context of STAT-1 deficiency, so it is 
possible that mIL-12 may rescue the impaired NK cell activity in SCID-Beige mice (Lee 
et al., 2000). Moreover, macrophages derived from beige mice are capable of 
macrophage cytotoxicity factor (MCF)-induced lysis and antibody-dependent cell-
mediated lysis (ADCC) (Meerpohl et al., 1976; Roder and Duwe, 1979). Macrophages 
also express IL-12Rβ2 and IL-12 stimulation resulted in a positive feedback loop that 
amplifies IL-12 secretion (Grohmann et al., 2001). 
To test whether the enhanced anti-tumor efficacy in 19-28z/mIL-12 CAR T cell 
therapy may in part be attributed to paracrine effect of IL-12 on NK cells or 
macrophages, we generated 19-28z/hIL-12 CAR by replacing the murine flexi-IL-12 
region of 19-28z/mIL-12 with human flexi-IL-12 (Wagner et al., 2004). Since human 
IL-12 is not cross-reactive with mouse IL-12 receptor, treating a SCID-Beige mouse 
with 19-28z/hIL-12 should not affect host cells. We injected NALM-6 tumor cells into 
SCID-Beige mice followed by infusion with 19-28z, 19-28z/mIL-12, or 19-28z/hIL-12 
CAR T cells. As noted previously, 19-28z/mIL-12-treated mice had significantly greater 
overall survival compared to 19-28z-treated mice (p<0.0001, n=10). The majority (90%) 
of 19-28z/mIL-12-treated mice were tumor-free until day 69, and overall 60% of all 
mice survived on day 150 (Figure 5.2A). The 19-28z/hIL-12-treated mice also had 
significantly greater survival compared to 19-28z-treated mice with 20% overall 
survival on day 150 (p=0.0497, n=10). Differential tumor growth can also be observed 
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as early as day 34 after tumor administration as determined by bioluminescent imaging 
(Figure 5.2B). 
However, it is noteworthy that the overall survival of 19-28z/hIL-12 CAR T 
cell-treated mice was significantly lower compared to 19-28z/mIL-12 CAR T cell-
treated mice (p=0.0488, n=10). This suggests that the enhanced efficacy of 19-28z/mIL-
12 CAR T cells may in part be due to a paracrine effect of IL-12 on NK cells and/or 
macrophages. While NK cell activity is reduced in SCID-Beige mice, it is possible that 
IL-12 or other IL-12-induced cytokines can rescue this defect, resulting in enhanced NK 
cell-mediated anti-tumor activity. IL-12 may also induce macrophages towards an M1 
phenotype, supporting enhanced anti-tumor activity. 
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Figure 5.2 19-28z/hIL-12 CAR T cell therapy has reduced anti-tumor 
efficacy compared to 19-28z/mIL-12 CAR T cell therapy in vivo 
(A) SCID-Beige mice were inoculated (i.v.) with 1x106 NALM-6/GFPLuc 
tumor cells on day 0 and 1x107 CAR T cells on day 6. Data showing 60% long-
term survival of 19-28z/mIL-12 CAR T cell-treated mice compared to 20% 
survival in 19-28z/hIL-12 CAR T cell-treated mice (p=0.0488). 19-28z/mIL-12 
(p<0.0001) and 19-28z/hIL-12 (p=0.0497) T cell-treated mice have enhanced 
survival compared to 19-28z T cell-treated mice in which none of the mice in 
the latter group survived. n=10 mice from two independent experiments. (B) 
Representative bioluminescent imaging (BLI) of tumor progression following 
i.v. administration of NALM-6 tumor on day 13 and day 34. 
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CAR T cell persistence in vivo 
To further explain the mechanism of enhanced 19-28z/mIL-12 CAR T cell-
mediated in vivo anti-tumor efficacy, we assessed persistence of CAR T cells in 
peripheral blood of 19-28z, 19-28z/mIL-12, and 19-28z/hIL-12 CAR T cell-treated 
mice at seven and 14 days after CAR T cell infusion. No significant difference in 
percentage of CD3+CAR+ T cells can be observed between 19-28z, 19-28z/mIL-12, and 
19-28z/hIL-12 CAR T cell-treated mice at seven days post-T cell administration as 
determined by flow cytometry on peripheral blood samples from treated mice (Figure 
5.3A). Furthermore, CD3+CAR+ T cells were no longer detectable at 14 days post-T cell 
administration (Figure 5.3B). 
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Figure 5.3 CAR T cell persistence in NALM-6 tumor-bearing mice 
SCID-Beige mice were inoculated (i.v.) with 1x106 NALM-6 tumor cells on 
day 0 and 1x107 CAR T cells on day 14.  At seven days (A) and 14 days (B) 
after CAR T cell infusion, peripheral blood was evaluated for CAR and CD3 
expression by flow cytometry. (A) Representative data (left panel) and 
summary (right panel) of frequency of CD3+CAR+ T cells at seven days post-T 
cell injection of ten mice from two independent experiments. (B) Representative 
data (left panel) and summary (right panel) of frequency of CD3+CAR+ T cells 
at 14 days post-T cell injection of five mice from two independent experiments. 
NS, p=not significant. 
55 
 
CHAPTER 6: IL-12-SECRETING CAR T CELLS RESIST TREG SUPPRESSION 
 
Exogenous IL-12 induces 19-28z CAR T cell resistance to nTreg suppression 
Having established the effect of mIL-12 in enhancing anti-tumor efficacy of 
CAR T cells both in vitro and in vivo, we next considered whether mIL-12 can mediate 
nTreg resistance in human CAR T cells. We hypothesized that mIL-12-stimulated CAR 
T cells may resist nTreg suppression, considering the enhanced proliferation and 
cytotoxic potential of mIL-12-stimulated CAR T cells. IL-2 and IL-15 have also been 
demonstrated to enhance anti-tumor efficacy of T cell therapy (Nastala et al., 1994; 
Rosenberg et al., 1986). We therefore tested whether these cytokines may improve 
resistance to nTreg suppression. 
 
 
 
Figure 6.1 nTreg FOXP3 expression after expansion 
CD4+CD25hi nTregs were isolated from peripheral blood by magnetic bead 
separation and expanded with anti-CD3/CD28 beads in the presence of IL-2 
and rapamycin. Data showing FOXP3 and CD25 expression after three weeks 
of expansion as assessed by flow cytometry. 
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We isolated nTregs from PBMCs, and generated a viable population of nTregs 
that retained high FOXP3 expression after three weeks of expansion (Figure 6.1). We 
then co-cultured the expanded nTregs with activated CAR T cells in the presence of IL-
2, murine IL-12, and IL-15. nTregs suppressed the proliferation of 19-28z CAR T cells 
in response to anti-CD3/CD28 bead stimulation, resulting in a significant reduction in 
CAR T cell proliferation (36.55%) compared to 19-28z CAR T cells cultured without 
nTregs (60.67%) after 72 hours of anti-CD3/CD28 bead stimulation (p=0.0152, n=6; 
Figure 6.2). The addition of exogenous mIL-12 significantly protected the capacity of 
19-28z CAR T cells to proliferate in response to stimulation in the presence of nTregs 
(57.45%) (p=0.0260, n=6). In contrast, culturing 19-28z CAR T cells in the presence of 
IL-2 (p=0.0931, n=6) or IL-15 (p=0.3052, n=6) had no significant effect on nTreg 
resistance. Furthermore, we did not observe any nTreg resistance in 19-28z CAR T cells 
cultured in the presence of IFN-γ (p=0.7619, n=3), IL-7 (p=0.1667, n=3), IL-18 
(p=0.7143), IL-21 (p=0.2619, n=3), and IL-23 (p=0.4762, n=3; Figure 6.3). 
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Figure 6.2 19-28z CAR T cells resist nTreg suppression of proliferation in 
the presence of mIL-12 
5x105 CFSE-labeled 19-28z CAR T cells were stimulated with anti-CD3/CD28 
beads and co-cultured with 5x105 nTregs in the presence of exogenous IL-2, IL-
12, or IL-15 for 72 hours. (A) Representative data showing the percentage of 
proliferating T cells gated in the CFSE-diluted population. (B) Combined 
summary of six independent experiments. *p<0.05; NS, p=not significant. 
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We further tested whether mIL-12 can protect the cytolytic capacity of 19-28z 
CAR T cells in the presence of nTregs. We co-cultured 19-28z CAR T cells in the 
presence or absence of nTregs for 24 hours at a 1:1 ratio followed by a 24 hour co-
culture with CD19-expressing Raji tumor cells. In contrast to Pz1 CAR T cells (which 
targets PSMA), 19-28z CAR T cells fully eradicated CD19+ Raji tumor cells in the 
absence of nTregs (Figure 6.4). While nTregs inhibit the ability of the 19-28z CAR T 
cells to kill Raji tumor cells, 19-28z CAR T cells can overcome this suppression in the 
presence of exogenous mIL-12. This was not observed in the presence of exogenous IL-
2 or IL-15 (Figure 6.4). 
 
Figure 6.3 IFN-γ, IL-7, IL-18, IL-21, and IL-23 do not have an effect on the 
capacity of 19-28z CAR T cells to resist nTreg suppression 
5x105 CFSE-labeled 19-28z CAR T cells were stimulated with anti-CD3/CD28 
beads and co-cultured with 5x105 nTregs in the presence of exogenous IL-12, 
IFN-γ, IL-2, IL-7, IL-15, IL-18, IL-21, and IL-23 for 72 hours. *p<0.05, n=3; 
NS, p=not significant relative to the “19-28z + nTreg” group. 
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19-28z/mIL-12 CAR T cells resist nTreg suppression in vitro 
To further assess whether 19-28z/mIL-12 CAR T cells similarly have the 
capacity to resist nTreg suppression, we performed a CFSE proliferation assay with T 
cells transduced to express 19-28z or 19-28z/mIL-12. We co-cultured 19-28z or 19-
28z/mIL-12 CAR T cells in the presence of nTregs and evaluated their proliferative 
capacity by measuring CFSE dilution after 72 hours of anti-CD3/CD28 bead stimulation. 
As we have demonstrated earlier, 19-28z CAR T cells had significantly reduced 
proliferation in the presence of nTreg (10.2%) compared to 19-28z CAR T cells cultured 
in the absence of nTregs (57.6%) after anti-CD3/CD28 bead stimulation (p=0.05, n=3) 
 
 
Figure 6.4 19-28z CAR T cells resist nTreg suppression of cytotoxic activity 
in the presence of mIL-12 
CAR T cells were co-cultured with nTregs at a 1:1 nTreg:CAR ratio for 24 
hours. Raji cells were then added in the presence or absence of mIL-12 for an 
additional 24 hours. (A) Representative data showing the percentage of CD19+ 
tumor cells and CD3+ T cells after co-culture as determined by flow cytometry 
after anti-CD19 and anti-CD3 antibody staining. (B) Summary of four 
independent experiments.  *p<0.05, n=4. 
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(Figure 6.5A-B). In contrast, 19-28z/mIL-12 CAR T cells retained proliferative capacity 
in the presence of nTregs (64.9%) after anti-CD3/CD28 bead stimulation (p=0.05; 
Figure 6.5A-B). 
We next investigated whether 19-28z/mIL-12 CAR T cells are also refractory to 
nTreg-mediated suppression of tumor lysis. We co-cultured 19-28z or 19-28z/mIL-12 
CAR T cells in the presence nTregs for 24 hours at a 1:1 ratio followed by a 24 hour co-
culture with CD19-expressing Raji tumor cells. We evaluated cytotoxic activity of CAR 
T cells based on the percentage of tumor cells that remained as assessed by flow 
cytometry. In contrast to 19-28z CAR T cells which had a reduced capacity to kill Raji 
tumor cells in the presence of nTregs, cytotoxic function of 19-28z/mIL-12 CAR T cells 
was maintained in the presence of nTregs (Figure 6.5C-D). 
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19-28z/mIL-12 CAR T cells resist nTreg suppression in vivo and promote long-
term survival of tumor-bearing mice 
We have previously established an in vivo nTreg xenotransplant mouse model 
in which we showed that 19z1-transduced nTregs can traffic to the site of Raji tumor 
and markedly inhibit effector 19-28z CAR T cells (Teff) from eradicating the tumor. 
 
 
Figure 6.5 19-28z/mIL-12 CAR T cells resist nTreg suppression in vitro 
(A-B) 19-28z/mIL-12 CAR T cells resist nTreg suppression of proliferation. 
CAR T cell proliferation after three days of anti-CD3/CD28 bead stimulation 
and nTreg co-culture. Data showing the percentage of proliferating T cells gated 
in the CFSE-diluted population (*p=0.05, n=3). (C-D) 19-28z/mIL-12 CAR T 
cells resist nTreg-mediated suppression of cytotoxicity. CAR T cells were co-
cultured with nTregs at a 1:1 nTreg:CAR ratio for 24 hours. Raji cells were then 
added and the cells were analyzed by flow cytometry 24 hours later (*p<0.05, 
n=4). 
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We demonstrated that 19-28z CAR T cells lose its capacity to eradicate Raji tumors at 
a nTreg:Teff ratio of as low as 1:8 in a xenotransplant SCID-Beige mouse model (Lee 
et al., 2011). Here, we demonstrate that 19-28z/mIL-12 CAR T cell-treated mice had 
enhanced survival compared to control mice treated with 19-28z CAR T cells. The 19-
28z/mIL-12 CAR T cell-treated mice had a long-term survival of 75%, even at a high 
nTreg:Teff ratio of 1:1 (p<0.0001, n=16; Figure 6.6). 
 
  
 
 
Figure 6.6 19-28z/mIL-12 CAR T cell therapy has enhanced anti-tumor 
efficacy compared to 19-28z CAR T cell therapy under nTreg-suppressing 
conditions in vivo 
SCID-Beige mice were inoculated (i.v.) with 5x105 Raji tumor cells on day 0, 
1x107 19z1 CAR nTregs on day 5, and 1x107 CAR T cells on day 6. 75% long-
term survival of 19-28z/mIL-12 CAR T cell-treated mice compared to 0% 
survival of 19-28z CAR T cell-treated mice (p<0.0001, n=16 from three 
independent experiments). No significant difference between mouse treated 
with 19-28z CAR T cell compared to Pz1
 CAR T cell-treated mice (p=0.0618). 
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CHAPTER 7: EFFECT OF IL-12 AND IFN-γ ON TREGS AND TUMOR CELLS 
 
Having demonstrated the effect of IL-12 on the ability of CAR T cells to resist 
nTreg suppression both in vitro and in vivo, we next initiated studies investigating the 
underlying mechanisms of IL-12-mediated nTreg resistance. In our SCID-Beige nTreg 
xenotransplant model, there are three cell types that may potentially respond to IL-12 
secretion in the tumor microenvironment (Figure 7.1): (1) CAR T cells may respond to 
IL-12 in an autocrine fashion allowing resistance to anti-proliferative signals. CAR T 
cells may also indirectly respond to IFN-γ, a major cytokine induced by IL-12, which 
can further enhance CAR T cell function. (2) nTregs may respond to IL-12 directly or 
indirectly through IFN-γ that dampens its suppressive capacity. (3) Raji tumor cells may 
respond to IL-12 or other IL-12-induced cytokines that may weaken the capacity of Raji 
tumor cells to survive in the tumor microenvironment. 
IL-12-mediated nTreg resistance requires constant IL-12 stimulation 
We first examined the contribution of IL-12 on CAR T cells. As we have 
demonstrated, IL-12 enhances the capacity of CAR T cells to proliferate and resist 
nTreg-mediated suppression. However, it is unclear if a single dose of IL-12 will induce 
permanent changes in the CAR T cells rendering them resistant to nTregs without 
further IL-12 stimulation. To address this question, we pre-incubated effector T cells 
(Teff) cells in the presence of mIL-12 for 24 hours then tested whether the Teff cells 
can still resist nTreg suppression after washing out the mIL-12 in the media. In contrast 
to Teff cells that were cultured in the presence of mIL-12, Teff cells pre-incubated with 
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mIL-12 (12Teff) cells no longer resist nTreg suppression after loss of mIL-12 
stimulation (Figure 7.2). Similarly, Teff cells pre-incubated with IFN-γ (γTeff) do not 
have the capacity to resist nTreg suppression (Figure 7.2). These results are consistent 
with required persistent IL-12 stimulation of Teff cells as pre-incubation of Teff cells 
with IL-12 failed to result in retained resistance to nTregs. 
 
 
 
Figure 7.1 Mechanism of IL-12-mediated nTreg resistance 
Schematic diagram depicting the three major cell types, CAR T cells, nTregs, 
and B cell tumor, that may potentially respond to IL-12 secretion in the tumor 
microenvironment. Hypothetically, IL-12 secreted by 19-28z/mIL-12 CAR T 
cells may have a direct effect on all three cell types or indirect effect through 
IFN-γ or other cytokines induced by IL-12 
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IL-12-mediated nTreg resistance is not due to its effect on nTreg cells 
To assess whether IL-12 secretion by CAR T cells may impact the function of 
nTregs, we first determined whether nTregs express the IL-12 and IFN-γ receptors to 
directly respond to these cytokines. We verified that a substantial percentage of nTregs 
expressed IL-12Rβ2 after 48 hours of activation, indicating that nTreg function may be 
influenced by IL-12 secretion (Figure 7.3A). Furthermore, a substantial percentage of 
 
 
Figure 7.2 IL-12-mediated nTreg resistance requires constant IL-12 
stimulation 
CFSE-labeled Teff cells were pre-incubated with mIL-12 (12Teff) or IFN-γ 
(γTeff) for 24 hours. After thorough washing, 5x105 of the pre-incubated Teff 
cells were co-cultured with 5x105 nTregs for 72 hours after anti-CD3/CD28 
bead stimulation. Control CFSE-labeled Teff cells were co-cultured with 
nTregs in the presence or absence of mIL-12. *p<0.05; NS, p=not significant. 
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nTregs also expressed IFN-γR1, indicating that nTreg function may also be influenced 
by IFN-γ (Figure 7.3B). 
 
Since nTregs express both IL-12 and IFN-γ receptors, we reasoned that one 
possible explanation for the reduced nTreg suppressive activity may be a direct impact 
of IL-12 or IFN-γ on Treg function. To test this hypothesis, we pre-cultured nTreg cells 
in the presence or absence of mIL-12 for 24 hours, washed out the mIL-12 in the media, 
then assessed whether the nTregs retain suppressive function. In a 72 hour CFSE anti-
CD3/CD28 bead stimulated proliferation assay, we observed that nTregs no longer 
suppress Teff cells in the presence of mIL-12 as expected. However, nTregs that were 
pre-incubated with mIL-12 (12Treg) retained suppressive capacity (Figure 7.4). 
Similarly, nTregs that were pre-incubated with IFN-γ (γTreg) also retained suppressive 
 
 
Figure 7.3 nTregs express IL-12Rβ2 and IFN-γR1 
(A) IL-12Rβ2 expression on nTregs and T cells that were stimulated with anti-
CD3/CD28 beads for 48 hours as determined by flow cytometry following 
staining with an antibody specific for IL-12Rβ2. (B) IFN-γR1 expression in 
resting T and nTreg cells as determined by flow cytometry following staining 
with an antibody specific for IFN-γR1. 
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capacity (Figure 7.4). This suggests that the effect of IL-12 on nTreg resistance is not 
likely due to a direct impact of IL-12 or IFN-γ on the suppressive function of nTregs. 
 
While IL-12 and IFN-γ do not appear to have a direct impact on the suppressive 
capacity of nTregs, we reasoned that IL-12-mediated nTreg resistance may be due to 
the impact of IL-12 or IFN-γ on the loss of the intrinsic proliferative capacity of nTregs. 
To determine whether IL-12 and IFN-γ have any effect on nTreg proliferation, we 
 
 
Figure 7.4 Effect of IL-12 and IFN-γ on nTreg suppression 
nTreg cells were pre-incubated with mIL-12 (12Treg) or IFN-γ (γTreg) for 24 
hours. After thorough washing, 5x105 of the pre-incubated nTreg cells were co-
cultured with 5x105 CFSE-labeled Teff cells for 72 hours after anti-CD3/CD28 
bead stimulation. Control CFSE-labeled Teff cells were co-cultured with 
nTregs in the presence or absence of mIL-12. *p<0.05; NS, p=not significant. 
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cultured CFSE-labeled nTregs in the presence of IL-12 or IFN-γ for 72 hours after anti-
CD3/CD28 stimulation. We demonstrated that IL-12 does not reduce nTreg 
proliferation but actually induces a significant increase in nTreg proliferation (Figure 
7.5). Furthermore, we did not observe any difference in proliferation between nTregs 
that were stimulated in the presence or absence of IFN-γ. 
 
 
 
Figure 7.5 Effect of IL-12 and IFN-γ on nTreg proliferation 
CFSE-labeled nTregs were stimulated with anti-CD3/CD28 beads in the 
presence or absence of IL-12 or IFN-γ for 72 hours. Percentage of proliferating 
nTregs was determined by evaluating the CFSE-diluted T cells among the 
FOXP3+ cell population. *p<0.05; NS, p=not significant. 
69 
 
IL-12 has no intrinsic effect on Raji tumor cells 
To assess whether IL-12 may directly affect tumor viability, we next 
investigated the effect of IL-12 or IFN-γ on Raji tumor cells. We first determined 
whether Raji tumor cells express IL-12 or IFN-γ receptors to directly respond to these 
cytokines. No expression of IL-12Rβ2 was observed in Raji tumor cells (Figure 7.6A). 
However, Raji tumor cells do express IFN-γR1 (Figure 7.6B). 
 
Since Raji cells may respond to IFN-γ, we tested whether IFN-γ can induce IL-
12Rβ2 expression in Raji cells. To determine the effect of IFN-γ on IL-12Rβ2 
expression in Raji cells, we cultured Raji cells at three different concentrations of IFN-
γ. However, we do not observe any differential expression of IL-12Rβ2 compared to 
activated T cell control (Figure 7.7A). While IFN-γ may not have an effect on IL-12Rβ2, 
it is possible that IFN-γ may have a direct impact on the survival and proliferation of 
Raji cells. However, we did not observe any effect of IFN-γ on the survival of Raji 
tumor cells as assessed by the expression of BCL-2 in Raji cells after IFN-γ stimulation 
 
 
Figure 7.6 Expression of IL-12Rβ2 and IFN-γR1 in Raji tumor cells 
Raji cells and activated T cells were assessed for the expression of (A) IL-
12Rβ2 and (B) IFN-γR1 by flow cytometry. 
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(Figure 7.7B). Stimulating Raji cells with IFN-γ also had no significant effect on the 
ability of Raji cells to proliferate (Figure 7.7C). 
 
Since the 19-28z/mIL-12 CAR T cells have the potential to express many other 
cytokines besides IFN-γ upon antigen stimulation, it is possible that any of these other 
 
 
Figure 7.7 IFN-γ has no effect on Raji tumor cells 
Raji cells were cultured in IFN-γ at the indicated concentrations for 24 hours 
and assessed for (A) IL-12Rβ2 and (B) BCL-2 expression by flow cytometry. 
(B) Raji cells were labeled with CFSE and cultured in IFN-γ at the indicated 
concentrations for 72 hours. Percentage of proliferating Raji cells was 
determined by evaluating CFSE-diluted Raji cells. Data represent three 
independent experiments. NS, p=not significant. 
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cytokines may have an effect on Raji cells. To rule out this possibility, we cultured Raji 
cells in the supernatant of CAR T cells that have been previously activated with AAPCs 
and assessed IL-12Rβ2 expression. Whether the Raji cells were stimulated with 19-28z 
or 19-28z/mIL-12 CAR T cell supernatant, we did not observe any differential IL-
12Rβ2 expression as compared to unstimulated Raji cells (Figure 7.8A). Stimulating 
Raji cells with the supernatant of 19-28z/mIL-12 or 4H11-28z/mIL-12 CAR T cells also 
have no observable effect on BCL-2 expression as compared to Raji cells stimulated 
with 19-28z or 4H11-28z CAR T cells, respectively (Figure 7.8B). Furthermore, co-
culturing Raji cells with 4H11-28z and 4H11-28z/mIL-12 CAR T cells have no 
differential effect on the capacity of Raji cells to proliferate (Figure 7.8C). We conclude 
that IL-12-mediated nTreg resistance is not likely due to the impact of IL-12 on Raji 
tumor cells. 
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Figure 7.8 Cytokines secreted by 19-28/mIL-12 CAR T cells have no effect 
on Raji tumor cells 
(A-B) 2x106 CAR T cells were stimulated with 3T3-AAPC (3T3-CD19/CD80 
or 3T3-MUC16/CD80) for 24 hours. The supernatant of T cell culture was used 
to culture Raji cells for an additional 24 hours. (A) IL-12Rβ2 and (B) BCL-2 
expression were assessed by flow cytometry. Data represent three independent 
experiments. (C) 1x106 CFSE-labeled Raji cells were co-cultured with 1x106 
activated 4H1128z or 4H1228z/mIL-12 CAR T cells for 72 hours. Control Raji 
cells were cultured in the presence or absence of mIL-12. Data represent three 
independent experiments. NS, p=not significant. 
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CHAPTER 8: DISCUSSION 
 
The discipline of adoptive cell therapy (ACT), a form of cancer immunotherapy, 
started nearly half a century ago when it was first discovered that lymphocyte infiltration 
resulted in spontaneous cancer regression in several types of cancer (Rosenberg et al., 
1972). As it became clear that these tumor-infiltrating lymphocytes (TILs) were 
responsible for cancer regression, cancer therapies that harness the anti-tumor faculty 
of immune cells have been developed over the years. While considerable progress has 
been made in recent years with the advent of tumor-specific TCR and CAR T cell 
engineering, successful application of cancer immunotherapy remains a challenge for 
most cancers (Duong et al., 2015). 
Several important obstacles need to be addressed in order for an immunotherapy 
to successfully treat cancer. First, it is important to select a tumor-associated antigen 
(TAA) that is specific to the cancer but absent in normal cells to avoid on-target off-
tumor toxicity. Engineered T cells that express TCR or CAR that recognize the TAA 
must be able to efficiently traffic to the tumor. Once at the site of the tumor, tumor-
targeted T cells must receive both signal 1 (TCR) and signal 2 (co-stimulation) to be 
fully activated and overcome anergy. Upon activation, tumor-targeted T cells must be 
able to expand adequately and persist long enough to eradicate cancer.  Moreover, the 
T cells must survive and retain function in a tumor microenvironment. This includes the 
presence of immunosuppressive Tregs, TAMs, and MDSCs as well as expression of 
inhibitory factors such as PD-L1, TGF-β and IL-10. 
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Our studies described a novel cancer immunotherapy that combines the clinical 
advantages of CAR T cells with the anti-tumor effect of localized IL-12 secretion. Such 
a therapy addresses many of the challenges of cancer immunotherapy. We demonstrated 
that IL-12 enhances proliferation, improves effector function, and confers T cells to 
resist Treg suppression in the context of cancer. 
Tumor Associated Antigen 
In our studies, 19-28z/mIL-12 CAR T cells specifically recognize the CD19 
antigen expressed on normal B cells as well as B cell tumors. CD19 antigen is a nearly 
ideal TAA as it is expressed in virtually all forms of B cell leukemia and lymphoma. 
While CD19 is also expressed in most stages of B cell development, it is absent in 
pluripotent stem cells in the bone marrow. CD19-targeted CAR T cell therapy may lead 
to B cell aplasia as a result of on-target off-tumor toxicity. However, the toxic effect of 
B cell aplasia can be countered by therapeutic immunoglobulin infusion and restored by 
de novo B cell differentiation from pluripotent stem cells in the bone marrow after 
therapy. 
T Cell Activation and Proliferation 
Classical T cell activation requires two signals – TCR signaling upon antigen 
recognition (signal 1) and a co-stimulatory signal provided by activated antigen 
presenting cells (signal 2). Absence of the latter signal induces activated T cells into a 
non-responsive state known as anergy (Smith-Garvin et al., 2009). Activated T cells 
eventually succumb to activation-induced cell death (AICD) through Fas ligation-
induced caspase activation. On the other hand, co-stimulatory signaling such as CD28 
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binding to CD80 or CD86 have been shown to upregulate survival signals BCL-XL and 
FLIP while downregulating Fas ligand (FasL) (Budd, 2001). In addition to the two 
primary signals, Mescher and colleagues demonstrated that IL-12 can serve as a signal 
3, which is required for activation of naïve T cells but not antigen-experienced memory 
T cells (Schmidt and Mescher, 2002). Indeed, first generation CAR T cells that received 
only signal 1 lack the capacity to proliferate and persist compared to second generation 
CAR T cells that received both signals 1 and 2 (Savoldo et al., 2011). Second generation 
CAR T cells may demonstrate superior anti-tumor efficacy against tumor compared to 
first generation CAR T cells, but repeated expansion of such T cells results in eventual 
exhaustion in the absence of survival factors such as IL-15 (Brentjens et al., 2003). 
In our studies, we provided signal 3 by means of exogenous IL-12 or constitutive 
secretion of IL-12 by the CAR T cells. In both cases, we demonstrated that IL-12 
enhances the proliferative capacity of CAR T cells (Figure 3.1, 4.5). Moreover, 19-
28z/mIL-12 CAR T cells retain this proliferative capacity after repeated antigen 
exposure (Figure 4.7). Others have also reported that IL-12 induces proliferation and 
long term survival of T cells in vitro (Bertagnolli et al., 1992; Salgado et al., 2002). Our 
data are consistent with Mescher’s studies, demonstrating that IL-12 is required for 
clonal expansion and enhanced cytotoxic activity of T cells (Curtsinger et al., 2003). 
IL-12-Secreting CAR T Cells 
Despite enhanced anti-tumor efficacy of systemic IL-12 as signal 3 in preclinical 
studies, early clinical trials using systemic high dose IL-12 infusion resulted in severe 
toxicity in which patients developed flu-like symptoms, rapid leukopenia, and liver 
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dysfunction that in some cases was fatal (Car et al., 1999; Leonard et al., 1997). To 
further explore the anti-tumor effects of IL-12, it is therefore imperative to develop a 
delivery system that allows IL-12 to be selectively administered directly within the 
tumor microenvironment. Wagner and colleagues first explored this possibility by 
demonstrating that “flexi-IL-12”-transduced EBV-specific CTLs produce IL-12 only in 
the presence of antigenic stimulation (Wagner et al., 2004). 
Several recent reports further established that it is possible to deliver IL-12 to 
the site of the tumor and induce tumor regression by adoptively transferring IL-12-
transduced tumor-targeted T cells. We reported in a hCD19 transgenic C57BL/6 EL4 
mouse tumor model that mIL-12-secreting CD19-targeted CAR T cells eradicated tumor 
in the absence of prior lymphodepletion with no evidence of systemic toxicity (Pegram 
et al., 2012). Restifo and colleagues demonstrated in a murine Pmel-1 melanoma model 
that tumor-targeted T cells modified to express IL-12 can enhance anti-tumor activity 
of tumor-targeted T cells (Kerkar et al., 2010). Similarly, treatment with human IL-12-
secreting CAR T cells targeted to the angiogenic VEGF receptor successfully eradicated 
five different types of syngeneic tumors, including melanoma, sarcoma, and colorectal 
adenocarcinoma (Chinnasamy et al., 2012). Chmielewski and colleagues also 
demonstrated that treatment with CAR T cells engineered to release inducible IL-12 
upon CAR engagement resulted in tumor eradication that is dependent on macrophage 
activation (Chmielewski et al., 2011). 
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Central Memory Phenotype and T Cell Persistence 
Resting T cells exist as naïve (TN), central memory (TCM), and effector memory 
(TEM) T cell populations. Whereas TN cells are CD45RA
+CD45RO-, TEM and TCM are 
CD45RA-CD45RO+. TN cells and TCM cells are CCR7
+CD62L+ while TEM cells are 
CCR7-CD62L- (Mueller et al., 2013). It has been demonstrated using mouse OT-I cells 
that exogenous IL-12 priming induces the survival of CD8+CD62Lhi TCM-like cells, 
which results in enhanced anti-tumor activity following adoptive cell transfer (Díaz-
Montero et al., 2008). A TCM-like phenotype may be clinically relevant as Riddell and 
colleagues have demonstrated in macaque monkeys that adoptively transferred CMV-
specific T cells derived from CD8+CD62L+ TCM-like cells have long term persistence 
when compared to transfer of Teff cells (Berger et al., 2008). More recently, Riddell 
and colleagues also demonstrated the synergistic improvement in survival of Raji 
tumor-bearing NOD scid gamma (NSG) mice treated with CD19-targeted CAR T cells 
derived from a combination of CD4 and CD8 TCM subsets (Sommermeyer et al., 2015). 
As a result of these studies, clinical grade CD19-targeted T cells derived from 
CD8+CD62L+ T cells are being tested in clinical trials of B cell malignancy (Terakura 
et al., 2012; Wang et al., 2011b). 
Consistent with these studies, we found that a higher proportion of the 19-
28z/mIL-12 CAR T cells display a CCR7+CD62L+ TCM-like phenotype (Figure 4.6). 
Among the CCR7+CD62L+ population, some of the T cells display CD45RO expression 
while others display CD45RA expression (data not shown). As all the CAR T cells were 
antigen-experienced, the CD45RA+CCR7+CD62L+ population in our data are not 
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typical TN cells. Restifo and colleagues have recently described a new class of memory 
T cell subset known as T stem cell memory (TSCM) characterized by CD45RO
-
CD45RA+CCR7+CD62L+CD95+IL-2Rβ+ which has the highest proliferative capacity 
and anti-tumor efficacy among memory T cells (Gattinoni et al., 2011). It is possible 
that the TN-like cells seen in 19-28z/mIL-12 CAR T cells are actually TSCM cells, though 
this requires further investigation. Additionally, future studies on the effect of IL-12 on 
TSCM differentiation will need to be formally tested. 
To further test whether this enhanced CCR7+CD62L+ TCM-like phenotype seen 
in 19-28z/mIL-12 CAR T cells may result in enhanced in vivo persistence, we infused 
19-28z and 19-28z/mIL-12 CAR T cells into tumor-bearing mice and assessed CAR T 
cell persistence at seven and 14 days post-infusion. In our study, we did not observe 
significant difference in persistence of 19-28z/IL-12 CAR T cells in our pre-clinical 
xenotransplant model as compared to 19-28z CAR T cells (Figure 5.3). However, in an 
ovarian xenotransplant solid tumor model, Koneru and colleagues observed enhanced 
persistence in 4H11-28z/IL-12 CAR T cells as compared to 4H11-28z CAR T cells 
(Koneru et al., 2015). In this latter model, the route of CAR T cell injection was 
intraperitoneal (i.p.) rather than systemic (i.v.) as in our studies, and relative rate of 
tumor growth, as well as the number of injected CAR T cells (2.5x106 vs. 1x107) all 
differ. These differences may all contribute to the persistence of CAR T cells in vivo. It 
remains to be seen whether IL-12-secreting CAR T cells may exhibit enhanced 
persistence in the clinical setting. 
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Cytotoxic Potential 
The primary role of CAR T cells in cancer immunotherapy is to initiate its 
cytotoxic function on the tumor cells. Our studies demonstrated that IL-12 enhances the 
production of granzyme B and perforin, two molecules essential for the cytotoxic 
activity of CTLs (Figure 3.2 and Figure 4.9A-B). Furthermore, co-culture of 19-
28z/mIL-12 CAR T cells with NALM-6 tumor cells resulted in reduced tumor cell 
survival compared to co-culture of 19-28z CAR T cells with NALM-6 tumor (Figure 
4.9D). Consistent with 19-28z/mIL-12 human CAR T cells, we have also demonstrated 
that IL-12-secreting murine CAR T cells (19mz/mIL-12) have elevated granzyme B and 
perforin production and have enhanced cytotoxic activity (Pegram et al., 2012). These 
data are consistent with the established function of IL-12 in enhancing cytotoxic activity 
of T lymphocytes (Aste-Amezaga et al., 1994). In addition to enhancing cytotoxic 
activity of T lymphocytes, IL-12 is also a potent inducer of NK cell killing (Kobayashi 
et al., 1989). Therefore, IL-12 secretion in 19-28z/IL-12 CAR T cell therapy has the 
potential to enhance killing of tumor cells by means of both autocrine T cell and 
paracrine NK cell stimulations. 
IL-12 and Treg Resistance 
In the tumor microenvironment, it has been well-established the important role 
of Tregs in suppressing anti-tumor efficacy of immunotherapy (Roychoudhuri et al., 
2015). Therefore, generating tumor-targeted T cells capable of resisting Treg 
suppression is an important step towards improving cancer immunotherapy. Many 
institutions have previously performed mouse studies suggesting the possible role of IL-
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12 in resisting Treg-mediated inhibition of Teff cells (Cao et al., 2009; Curran et al., 
2012; Feng et al., 2011; King and Segal, 2005; Koch et al., 2012; Zhao et al., 2012). 
However, an in vivo human T cell model demonstrating IL-12-mediated 
resistance to Treg suppression in the context of cancer has not yet to date been reported. 
Moreover, the underlying mechanism of IL-12-mediated Treg resistance remains 
controversial. For example, King and Segal proposed that IL-12-mediated CD4+CD25- 
T cell resistance to Treg inhibition is IFN-γ independent as mouse Treg-Teff co-cultures 
with IFN-γ failed to restore Teff cell function (King and Segal, 2005). Zhao and 
colleagues further demonstrated that while IL-12 induces increased IFN-γ expression in 
mouse Tregs, IFN-γ+ and IFN-γ- Tregs inhibit Teff cells equally well (Zhao et al., 2012). 
Feng and colleagues similarly demonstrated that FOXP3+ mouse Tregs can convert into 
IFN-γ+FOXP3+ Tregs in the presence of TGF-β and IL-12 that retain suppressive 
capacity (Feng et al., 2011). In contrast, Cao and colleagues showed evidence that IFN-
γ is at least in part responsible for IL-12-mediated reduction of mouse Treg cell survival 
as IL-12 failed to inhibit IFN-γR1-/- Treg cell expansion in vitro (Cao et al., 2009). In a 
syngeneic hCD19 transgenic C57BL/6 EL4 mouse tumor model, Pegram and colleagues 
also suggested that IFN-γ is likely responsible for Treg resistance as no mice survived 
following treatment with CD19-targeted IL-12-secreting CAR T cells derived from 
IFN-γ deficient mice (Pegram et al., 2012). Treg resistance may also be attributed to the 
capacity of IL-12-secreting cells to resist the immunosuppressive cytokine TGF-β, a 
signature Treg cytokine. As Wagner and colleagues demonstrated, “Flexi-IL-12 CTLs” 
can resist TGF-β-mediated inhibition of proliferation and cytotoxic activity in vitro 
(Wagner et al., 2004). 
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Our studies demonstrated for the first time the ability of human CAR T cells to 
resist Tregs in the context of IL-12. Both exogenous IL-12 stimulation and IL-12-
secreting CAR T cells have the ability to resist Treg suppression of proliferation and 
cytotoxic activity of CAR T cells (Figure 6.2, 6.4, 6.5). Furthermore, this ability to resist 
Treg suppression as seen in 19-28z/mIL-12 CAR T cells is also observed in the context 
of an in vivo Raji tumor xenotransplant mouse model. Compared to mice treated with 
19-28z CAR T cells, 19-28z/mIL-12 CAR T cell treatment resulted in improved survival 
of mice previously injected with tumor-targeted immunosuppressive Tregs (Figure 6.7). 
Our data suggest that the ability of 19-28z/mIL-12 CAR T cells to resist Treg 
suppression is not due to a paracrine effect of IL-12 on Raji tumor cells. We 
demonstrated that Raji cells do not respond to IL-12 stimulation (Figure 7.6), and other 
cytokines secreted by activated 19-28z/mIL-12 CAR T cells, including IFN-γ, have no 
effect on the proliferation and expression of the survival signal BCL-2 in Raji cells 
(Figure 7.7, 7.8). 
Therefore, IL-12-mediated resistance of Treg suppression is likely due to the 
effect of IL-12 on CAR T cells and/or Tregs. We demonstrated that both CAR T cells 
and Tregs express the receptors required to respond to IL-12 and IFN-γ stimulation 
(Figure 7.3). Stimulating Tregs with IL-12 resulted in a slight increase in the 
proliferation of Tregs, while stimulating Tregs with IFN-γ had no effect on Treg 
proliferation (Figure 7.5). To distinguish whether the effect of IL-12 was due to its effect 
on CAR T cells or Tregs, we pre-incubated CAR T cells or Tregs with IL-12 before 
testing the suppressive capacity of the Tregs. However, once the IL-12 was removed, 
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the Tregs retained its capacity to suppress CAR T cell proliferation in both cases (Figure 
7.2 and 7.4). These data suggest that pre-incubating CAR T cells or Tregs with IL-12 
does not permanently change the phenotype of CAR T cells or Tregs, resulting in 
resistance to suppression. In other words, IL-12 stimulation must be present at the time 
of CAR T cell and Treg co-culture to resist Treg suppression. 
To definitively distinguish whether IL-12-mediated resistance to suppression is 
due to the effect of IL-12 on T cells or Tregs, the following experiments will be 
performed in the future. We will perform the 72 hour IL-12-stimulated CFSE 
proliferation assay in the context of IL-12Rβ2 knockout (KO) in the Teff cells, the Tregs, 
or both cell types. Genetic knockout of IL-12Rβ2 may be achieved by using the 
CRISPR/Cas9 system prior to Teff-Treg co-culture (La Russa and Qi, 2015). In the 
context of normal Teff cells cultured with Treg IL-12Rβ2 KO cells, if the Teff cells can 
still proliferate in the context of IL-12 stimulation, then IL-12-mediated resistance to 
Treg suppression is likely due to an autocrine effect of IL-12 on Teff cells. This 
conclusion should be confirmed with the demonstration that Teff IL-12Rβ2 KO cells 
fail to resist suppression by normal Tregs in the context of IL-12 stimulation. We should 
also expect Treg IL-12Rβ2 KO cells to retain suppression of Teff IL-12Rβ2 KO cells 
in the context of IL-12 stimulation as neither Teff cells nor Tregs would be able to 
respond to IL-12 stimulation. As IL-12 is a potent inducer of IFN-γ, we can further test 
the contribution of IFN-γ by performing the same proliferation experiments in the 
context of IFN-γR1 KO in the Teff cells, the Tregs, or both cell types. 
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In addition to the in vitro CFSE proliferation experiments, we can further 
distinguish the effect of IL-12 on the adoptively transferred CAR T cells and the 
endogenous cells in a syngeneic tumor mouse model. Pegram and colleagues have 
demonstrated in a hCD19 transgenic C57BL/6 EL4 mouse tumor model that treatment 
with mIL-12-secreting CD19-targeted CAR T cells derived from C57BL/6 IL-12Rβ2 
deficient background resulted in reduced anti-tumor efficacy compared to treatment 
with cells derived from normal C57BL/6 mice (Pegram et al., 2012). This suggests that 
an autocrine effect of IL-12 on the transferred CAR T cells is necessary to resist Treg 
suppression. We can further test whether the effect of IL-12 on Tregs is necessary for 
resistance to Treg suppression in vivo by performing a syngeneic tumor model using 
FOXP3-Cre mice with the IL-12Rβ2 gene locus flanked by LoxP sites. This results in 
specific deletion of IL-12Rβ2 gene in the FOXP3+ Treg population. We can then test 
whether IL-12-secreting CAR T cells retain anti-tumor efficacy in this context. If true, 
then a paracrine effect of IL-12 on endogenous Tregs is not required for resistance to 
Treg suppression in vivo. Once we have eliminated the possibility that resistance to 
suppression requires a paracrine effect of IL-12 on Tregs, we can further study the 
mechanism of IL-12-mediated resistance to Treg suppression by performing gene arrays 
of the Teff cells that have been co-cultured with Tregs and IL-12 compared to the 
absence of IL-12 stimulation. Specific genes can then be identified and further tested by 
genetic knockout experiments. 
While our studies do not suggest any direct effect of IL-12 on Treg function and 
survival, IL-12 may have an indirect effect on the recruitment and function of Tregs, 
resulting in an environment that favors an anti-tumor response. Our in vitro cytokine 
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secretion study demonstrated that IL-12 may decrease the production of certain 
cytokines associated with Treg recruitment and function. Among the cytokines we 
observed, TARC/CCL17, MDC/CCL22, I-309/CCL1, IL-9, and IL-16 secretion were 
reduced in the IL-12-stimulated group compared to non-IL-12-stimulated controls 
(Appendix 1). Sakaguchi and colleagues have described the preferential recruitment of 
CCR4+ Tregs in melanoma tissue (Sugiyama et al., 2013). Since CCR4 responds to both 
TARC and MDC, it can be hypothesized that reduction in the production of TARC and 
MDC may result in decreased Treg recruitment in a syngeneic immunocompromised 
system. CCR8+FOXP3+ cells represent about 60% of all FOXP3+CD4+ memory T cells 
(Soler et al., 2006). Since I-309 recruits CCR8+ T cells, reduced I-309 secretion may 
also reduce Treg recruitment. IL-16 has also been demonstrated to both recruit existing 
Tregs as well as induce de novo FOXP3+ T cells (McFadden et al., 2007). Furthermore, 
IL-9 also enhances the suppressive function of FOXP3+ Treg cells (Elyaman et al., 
2009). Our xenotransplant immunocompromised mouse studies do not adequately 
account for the possible role of IL-12 in Treg recruitment. Future studies in a syngeneic 
tumor transplant model will need to be tested to formally address the role of these 
individual cytokines in IL-12-mediated Treg resistance in vivo. 
Effect of IL-12 on Myeloid Cells 
The benefit of using IL-12-secreting CAR T cell therapy likely extends beyond 
overcoming Treg-mediated inhibition. MDSCs, TAMs, and dendritic cells play a 
significant immunosuppressive role in many solid tumors (Gajewski et al., 2006). 
Restifo and colleagues proposed that IL-12 may enhance anti-tumor efficacy by 
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reprogramming MDSCs, macrophages, and dendritic cells to favor the support of CAR 
T cells (Kerkar et al., 2011). Evidence also suggests the importance of IL-12-mediated 
upregulation of Fas in myeloid cells with respect to tumor regression (Kerkar et al., 
2013). 
In our studies, we observed that 19-28z/mIL-12 CAR T cells are characterized 
by a Th1/Tc1-type immune response, producing high levels of the Th1 cytokine IFN-γ 
and low levels of the Th2 cytokines IL-5 and IL-13, and the Th17 cytokine IL-17 (Figure 
3.3, 4.4). High levels of IL-12-induced IFN-γ are especially effective in reprogramming 
macrophages towards an M1 phenotype, shifting away from the immunosuppressive 
M2 phenotype associated with TAMs (Martinez and Gordon, 2014). 
In Vivo Tumor Model 
In a NALM-6 SCID-Beige model, we demonstrated that 19-28z/mIL-12 CAR T 
cells significantly improved survival of NALM-6 tumor-bearing mice when compared 
to 19-28z CAR T cell treatment. A single infusion of 19-28z/mIL-12 CAR T cells 
resulted in 93.3% survival of treated mice (Figure 5.1). In contrast, treatment with 19-
28z CAR T cells resulted in only 6.67% long-term survival. This result is consistent 
with IL-12-secreting CAR therapy administration in a syngeneic immunocompromised 
system, where CD19 tumor-bearing mice treated with IL-12-secreting CAR T cells also 
resulted in improved survival compared to survival of mice treated with non-IL-12-
secreting CAR T cells (Pegram et al., 2012).  Furthermore, we demonstrated that the 
enhanced anti-tumor efficacy of 19-28z/mIL-12 CAR T cells is not entirely autocrine as 
19-28z/hIL-12 CAR T cell treatment resulted in lower overall mouse survival (20%) 
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compared to 19-28z/mIL-12 CAR T cell treatment (60%) on day 150 after tumor 
injection (Figure 5.2). This suggests that IL-12 secretion by 19-28z CAR T cells may 
have a paracrine effect on residual NK cells and/or macrophages, mediating indirect 
tumor lysis that contributed to the observed enhanced mouse survival after CAR T cell 
treatment. 
Until the development of 19-28z/mIL-12 CAR T cells, successful treatment of 
NALM-6 ALL tumor in vivo has been a challenge. Treating NALM-6 with multiple 
weekly doses of 19-28z CAR T cells resulted in merely 44% overall survival (Brentjens 
et al., 2007). Therefore, the significant improved survival as seen in treating NALM-6 
tumor with 19-28z/mIL-12 CAR T cells is an important step towards translating IL-12-
secreting CAR T cells to the clinic. As Pegram and colleagues demonstrated in a 
syngeneic EL4-tumor model, conditioning therapy as has been the current standard for 
CAR therapy may be eliminated when treating with CD19-targeted IL-12-secreting 
CAR therapy (Pegram et al., 2012). 
Concluding Remarks 
In this thesis, we present evidence that adoptively transferring tumor-targeted 
CAR T cells “armored” to secrete IL-12 may be a more effective approach to CAR T 
cell therapy for cancer. 19-28z/mIL-12 CAR T cells exhibit enhanced in vivo anti-tumor 
efficacy, enhanced proliferation, and resistance to Treg suppression. In contrast to 
toxicities reported in other pre-clinical studies of tumor targeted IL-12 secreting T cells, 
we did not observe any toxicity in 19-28z/mIL-12 CAR T cell-treated mice in this and 
previous studies (Kerkar et al., 2010; Pegram et al., 2012). This lack of associated 
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toxicity may in part be due to lower levels of IL-12 expression by our 19-28z/mIL-12 
CAR T cells. In our retroviral construct, the flexi-IL-12 gene was placed behind an IRES 
element, which lowers the expression of IL-12 in these T cells (Kim et al., 2011). 
Nevertheless, we acknowledge the inherent risk associated with cytokine therapy and 
plan to include a suicide vector such as inducible caspase-9 or truncated EGFR to 
enhance safety (Straathof et al., 2005; Wang et al., 2011a). 
Development of CAR T cell engineering for the treatment of cancer has come a 
long way from demonstrating the capacity of first generation CAR T cells to respond to 
antigen independent of HLA restriction to successful treatment of hematopoietic 
malignancies with second generation CAR T cells in clinical trials. We have learned the 
many obstacles associated with CAR T cell therapies, including the requirement to 
overcome the suppressive tumor microenvironment and the need to control cytokine 
release syndrome (CRS). The future of CAR T cell technology lies in overcoming these 
obstacles as we translate this therapy into the clinic. In this thesis, we have described 
one possible way to overcome these obstacles by introducing IL-12 in the CAR T cell 
environment. Our preclinical data demonstrated enhanced in vivo anti-tumor efficacy of 
CD19-targeted CAR T cells “armored” to secrete IL-12 which can be attributed to TCM-
like phenotype, enhanced cytotoxicity, and resistance to Treg suppression. Our 
successful preclinical studies suggest its potential clinical application for the treatment 
of B-CLL as well as the treatment of solid tumors. 
Successful translation of IL-12-secreting CAR T cell therapy in the clinic 
remains to be seen. Combining IL-12 secretion and CAR T cell engineering opens up a 
88 
 
new avenue for CAR T cell research. Should IL-12-secreting CAR T cell therapy fail to 
deliver efficacy in the clinic, CAR T cells “armored” with other more powerful  
immunomodulatory cytokines may be tested for cancer immunotherapy in the future. 
Perhaps, a combination of these cytokines may be essential for delivering optimal anti-
tumor response. As it became clear that several inhibitory factors such as CTLA-4 and 
PD-1 play a critical role in suppressing T cells in cancer, applying CAR therapy in 
combination with antibodies that neutralize such inhibitory factors is another area of 
CAR T cell research. As the study of CAR therapy has been focused mainly on T cells 
thus far, therapeutic application of this technology to other immune cell types may be 
explored in the future. As we continue to develop novel CAR T cell therapies for cancer, 
it is our sincere hope that safe CAR T cell therapy will one day be the standard of care 
for the treatment of cancer.  
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APPENDIX 
 
 
 
 
Appendix 1. Exogenous IL-12 reduces 19-28z CAR T cell secretion of 
cytokines that enhance Treg recruitment and function 
19-28z CAR T cells were stimulated with anti-CD3/CD28 beads in the presence 
or absence of exogenous mIL-12 for 48 hours and the supernatant was assessed 
by luminex. Secretion of I-309, IL-9, IL-16, MDC, and TARC in CAR T cells 
after stimulation. *p<0.05, n=3; NS, p=not significant. 
